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1. SUMMARY 
The breast cancer protective effect of an early pregnancy is well established in both humans 
and rodents, but the underlying mechanism is unclear. Since breast cancers are thought to 
originate from distinct mammary epithelial cell subtypes, we studied the effect of early parity 
on the gene expression and the functional properties of specific mouse mammary epithelial 
cell subpopulations. The latter were isolated by fluorescence-activated cell sorting (FACS) 
from parous and from age-matched virgin control mice. The isolated cell subpopulations 
were investigated further by unbiased genomic and bioinformatic methods, as well as by in 
vitro colony formation and by in vivo mammary gland reconstitution assays. The results of 
the transcriptome analysis showed an upregulation of differentiation genes and a pronounced 
decrease in the Wnt/Notch signaling ratio in the basal stem/progenitor cell subpopulation of 
parous mice. This was associated with a parity-induced downregulation of carcinogenic 
pathways and a reduction in the in vitro and in vivo proliferation potential. As a possible 
mechanism for reduced Wnt signaling in basal stem/progenitor cells, we found a more than 
threefold decrease in the expression of the secreted Wnt ligand Wnt4 in isolated total 
mammary cells from parous mice, which corresponded to a similar reduction in progesterone 
receptor positive and Wnt4-secreting cells in intact mammary epithelia. Notably, recombinant 
Wnt4 partially rescued the parity-induced in vitro proliferation defect of basal 
stem/progenitor cells, strongly suggesting a causal relation between decreased Wnt4 secretion 
and parity-induced molecular and functional changes of basal stem/progenitor cells in mice. 
In conclusion, the study shows that early parity induces differentiation, downregulates the 
Wnt/Notch signaling ratio and decreases the in vitro and in vivo proliferation potential of 
basal mammary stem/progenitor cells in mice. Thereby, the study not only delineates the 
cellular and molecular effects of early parity, but it also paves the way for future studies 
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examining whether inhibitors of Wnt signaling can be used to mimic the parity-induced 
protective effect against breast cancer. 
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3. INTRODUCTION 
Pregnancy is the most significant modifiable factor affecting a woman’s risk to develop 
breast cancer. Whilst a transient increase in breast cancer risk is observed immediately after 
parturition in women over 25 years, the long-term consequences of pregnancy include a 
strong and life-long breast cancer protective effect (Albrektsen et al., 2005; MacMahon et al., 
1970). Thereby, parity-induced tumor protection is more pronounced the earlier the 
pregnancy has occurred (MacMahon et al., 1970). Similarly, pregnancy and pregnancy-
mimicking hormones decrease the lifetime risk of developing mammary tumors in rodents 
(Medina, 2005; Rajkumar et al., 2007). Although early parity has been known for decades to 
change the pathophysiology of mammary glands, the underlying mechanism has only 
recently started to be unraveled.  
 
3.1 Mammary gland development and epithelial cell hierarchy 
3.1.1 Mammary gland development 
The mammary gland is unique in that it develops largely postnatally. Before puberty, the 
mammary gland contains only a rudimentary ductal system embedded in specialized stroma, 
known as the mammary fat pad in mice. With the onset of puberty (3 weeks in mice, 9-12 
years in humans), a network of ducts starts to grow from special structures described as 
terminal end buds (TEBs) in mice and observed also in humans (Anbazhagan et al., 1998; 
Williams and Daniel, 1983) (see Figure 3.1.1). The ductal system continues to grow after 
sexual maturity (5 weeks in mice, 11-14 years in humans) and reaches its full dimensions at 
about 8 weeks of age in mice and 18-24 years in humans (Anderson et al., 2003; Brisken and 
Duss, 2007; Howard and Gusterson, 2000; Russo and Russo, 2011). The mature virgin 
mammary gland consists of an extensive ductal network and numerous budding structures, 
known as alveolar buds in mice and terminal ductal lobuloalveolar units (TDLUs) in humans 
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(Britt et al., 2007; Cardiff and Wellings, 1999; Smalley and Ashworth, 2003). During 
pregnancy, the second stage of postnatal mammary gland development, alveolar buds or 
TDLUs expand their ductal branches and differentiate into milk-producing structures termed 
lobular alveoli during lactation. As lactation ceases, the mammary gland regresses to a virgin-
like state in a process called involution (Britt et al., 2007). This cycle of alveolar bud/TDLU 
expansion, differentiation into lobular alveoli and subsequent involution is repeated in 
following pregnancies. Notably, even though the involuted mammary gland resembles its 
virgin counterpart morphologically, it is not identical but retains vestiges of the preceding 
pregnancy (Cardiff and Wellings, 1999; Russo et al., 1982).  
 
 
 
Figure 3.1.1 Mammary gland development 
Schematic illustration of pre-pubertal and mature virgin mammary glands, as well as of 
mammary glands during pregnancy, lactation and after involution. TEB = terminal end bud, 
TDLU = terminal ductal lobuloalveolar unit, LN = lymph node 
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3.1.2 Cell hierarchy in the mammary gland epithelium 
The mammary epithelium in humans and mice is hierarchically organized. It essentially 
comprises luminal and basal cell compartments, which are separated from the surrounding 
stromal tissue by a basement membrane (see Figure 3.1.2). Thereby, differentiated luminal 
and basal (myoepithelial) epithelial cells have to be distinguished from luminal and basal 
progenitor as well as from mammary stem cells (Bruno and Smith, 2011; Visvader, 2009). 
Differentiated luminal cells have a central role in milk production during the lactation period. 
Furthermore, they comprise estrogen and progesterone receptor positive cells and are 
responsible for mediating the effects of estrogen and progesterone to other mammary 
epithelial cell types (Brisken and Duss, 2007; Sleeman et al., 2007). Differentiated 
myoepithelial cells constitute the contractile units of the mammary gland required for milk 
ejection. Luminal and basal progenitor cells are precursors for differentiated luminal and 
basal myoepithelial cells. They arise from mammary stem cells and are characterized by their 
ability to form colonies in vitro (Smalley et al., 1998; Stingl et al., 2001; Stingl et al., 2006). 
Mammary stem cells are long-lived, have the capability to produce the other cell types when 
needed and give rise to new mammary epithelial tissue during puberty and pregnancy 
(Visvader, 2009). Traditionally, mammary stem cells are functionally defined by their 
potential to reconstitute complete mammary epithelium when transplanted into epithelium-
free mouse mammary fat pads in vivo (Bruno and Smith, 2011; Deome et al., 1959). Such 
mammary stem cells, also known as mammary repopulating units (MRUs), are basally 
located and multipotent (able to form both luminal and basal epithelial cells) when 
transplanted into cleared fat pads (Shackleton et al., 2006; Sleeman et al., 2007; Stingl et al., 
2006). In the context of the intact adult mammary gland, recent lineage tracing experiments 
suggest a unipotent nature of basal mammary stem cells and the existence of additional 
luminal mammary stem cells. In these studies, multipotent mammary stem cells were 
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observed solely in the embryonic and possibly in the pregnant gland (van Amerongen et al., 
2012; Van Keymeulen et al., 2011). Mammary epithelial cells are separated by a basement 
membrane from the stromal tissue, which comprises fibroblasts, endothelial cells, 
macrophages, and adipocytes (Neville et al., 1998).  
 
 
 
Figure 3.1.2 Mammary epithelial structure and cell hierarchy 
Schematic cross-section through the mammary epithelium. Differentiated milk-producing 
luminal cells face the ductal lumen. They are closely associated with contractile basal 
myoepithelial cells, which serve in milk ejection. In the adult gland, differentiated luminal 
and basal myoepithelial cells develop from their corresponding progenitor cells. The entire 
epithelium is surrounded by a basement membrane and by stromal cells.  
 
Distinct mammary epithelial cell subpopulations can be isolated by fluorescence-activated 
cell sorting (FACS) using specific cell surface markers both from human breast tissue and 
from mouse mammary glands (Raouf et al., 2012; Shackleton et al., 2006; Sleeman et al., 
2007; Smalley et al., 2012; Stingl et al., 2006). In mice, the expression of heat stable antigen 
CD24, stem cell antigen1 (Sca1) and β1-integrin (CD29) or α6-integrin (CD49f), allows the 
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separation of luminal Sca1+ (CD24+High Sca1+), luminal Sca1- (CD24+High Sca1-), basal 
myoepithelial (CD24+Low Sca1- CD49fLow) and basal stem/progenitor (CD24+Low Sca1- 
CD49fHigh) cells. Luminal Sca1+ cells comprise estrogen receptor positive cells and display 
limited in vitro and no in vivo growth potential, suggesting a composition of many 
differentiated cells (Sleeman et al., 2007). Similarly, myoepithelial cells show little in vitro 
and in vivo growth capacity. They express smooth muscle actin (SMA) and are thought to 
represent basal differentiated cells (Smalley et al., 2012). In contrast, luminal Sca1- cells give 
rise to large and numerous colonies in vitro but have limited in vivo outgrowth capability, 
thereby featuring the classic phenotype of progenitor cells (Smalley et al., 2012; Smalley et 
al., 1998; Stingl et al., 2006). Finally, isolated CD49fHigh basal stem/progenitor cells are 
highly enriched in mammary repopulating units (MRUs) and show strong in vivo and 
moderate in vitro growth potential (Shackleton et al., 2006; Sleeman et al., 2007; Stingl et al., 
2006). These functional characteristics indicate a strong enrichment of basal mammary stem 
as well as progenitor cells in this cell subpopulation. The isolation of specific mammary 
epithelial cell subpopulations allows the study of cell subtype-specific properties and thus 
helps to understand intercellular communication in the mammary gland. 
 
 
3.2 Signaling pathways important for postnatal mammary gland development 
3.2.1 Hormones and Growth factors 
Postnatal mammary gland development is under hormonal control with central roles for the 
ovarian hormones estrogen and progesterone, as well as the hypophyseal hormones growth 
hormone and prolactin. The hormones bind to receptors in specific mammary cells and elicit 
intra- and intercellular signaling cascades, which in turn stimulate developmental changes.  
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Estrogen 
Ovarian estrogens are the major mitogenic factors for ductal morphogenesis 
(elongation/bifurcation) during puberty. Accordingly, ovariectomy in mice at 5 weeks of age 
causes failure of mammary ductal network development (Brisken and O'Malley, 2010; 
Neville et al., 2002), an effect which is rescued by implantation of 17-β-estradiol pellets into 
the mammary gland (Daniel et al., 1987). Mechanistically, estrogen appears to signal 
primarily via estrogen receptor alpha (ERα) to mediate ductal morphogenesis, and mice 
deficient in ERα exhibit severely stunted mammary development. Thereby, epithelial rather 
than stromal ERα expression is required, since ERα-/- epithelial cells fail to develop 
mammary ducts at puberty when transplanted into ERα wild type mammary fat pads, whereas 
ERα wild type epithelial cells form ductal networks in ERα-/- mammary fat pads 
(Bocchinfuso and Korach, 1997; Couse and Korach, 1999; Mallepell et al., 2006). Apart from 
estrogen itself, epidermal growth factor (EGF) also rescues ductal outgrowth in 
ovariectomized pubertal mice (Coleman et al., 1988), suggesting a downstream role of EGF-
mediated signaling in the estrogen pathway. Amongst the EGF family members, only 
amphiregulin is transcriptionally upregulated by estrogen in luminal epithelial cells during 
puberty and was shown to be necessary for estrogen-mediated ductal morphogenesis in gene-
knockout studies (Ciarloni et al., 2007). Following cleavage by ADAM17/TACE 
(Sunnarborg et al., 2002), estrogen-induced amphiregulin protein binds to and activates 
epidermal growth factor receptor (EGFR) expressed in the mammary gland stroma during 
ductal elongation (Schroeder and Lee, 1998) (see Figure 3.2.1a). Thereby, importance of 
stromal rather than epithelial EGFR is shown by transplantation experiments where EGFR-/- 
epithelium grafted into wild type fat pads produces normal ductal outgrowths, whereas wild 
type epithelium grafted into EGFR-/- stroma fails to develop ductal networks (Wiesen et al., 
1999). EGFR signaling in stromal cells is thought in turn to cause the release of mitogenic 
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signals to mammary epithelial cells. Thereby, fibroblast growth factor (FGF) 2 and FGF7 are 
especially attractive candidates for downstream growth promoting stimuli (Hynes and 
Watson, 2010; Sternlicht et al., 2005). The final result of the estrogen-ERα-amphiregulin-
EGFR-FGF signaling cascade is ductal elongation and bifurcation during puberty. 
 
 
 
Figure 3.2.1a Estrogen signaling cascade 
Estrogen binds to estrogen receptor alpha (ERα) in luminal epithelial cells and activates the 
expression of amphiregulin (Areg). Areg functions in paracrine signaling, binding to 
epidermal growth factor receptors (EGFRs) in stromal cells and inducing the stromal release 
of fibroblast growth factors (FGFs). Stromal FGFs are thought to stimulate basal stem cells to 
proliferate, ultimately leading to ductal growth (Pond et al., 2013). FGFR = fibroblast growth 
factor receptor 
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Growth hormone 
Peripubertal ductal morphogenesis is dependent not only on estrogen but also on growth 
hormone (GH) and its downstream effector insulin-like growth factor-1 (IGF-1) (Neville et 
al., 2002). This is demonstrated by the failure of estrogen to rescue mammary development in 
hypophysectomized, ovariectomized rats and its ability to restore duct formation if GH or 
IGF-1 is co-administered (Kleinberg et al., 2000; Sternlicht, 2006). Thereby, paracrine rather 
than endocrine IGF-1 appears essential for mammary development, since global IGF-1 
knockout mice exhibit significantly impaired duct formation whereas transgenic mice with 
liver-specific knockouts (resulting in 25% of wild type systemic IGF-1 levels) have normal 
ductal morphogenesis (Richards et al., 2004). Furthermore, IGF-1 receptor (IGF-1R)-
deficient mammary epithelial transplants demonstrate reduced ductal outgrowths in wild type 
cleared fat pads, suggesting that epithelial rather than stromal IGF-1R is required for 
mammary development (Bonnette and Hadsell, 2001). In contrast, GH receptor is dispensable 
in the epithelium, indicating an important role for stromal GH receptor (Gallego et al., 2001). 
Taken together, the GH-IGF-1 axis is an essential accessory signaling pathway next to 
estrogen for pubertal ductal morphogenesis.  
 
Progesterone 
Estrus cycle and pregnancy-induced ductal side-branching and alveolar morphogenesis in 
mature mammary glands require progesterone signaling. In line with this, deletion of both 
progesterone receptor (PR) isoforms, PR-A and PR-B, leads to failure of tertiary side-
branching and lobuloalveolar development in adult and pregnant mice whilst not affecting 
pubertal ductal morphogenesis (Soyal et al., 2002). Thereby, selective knockout experiments 
indicate that PR-B is essential and sufficient for these effects (Conneely et al., 2003), whereas 
tissue localization and transplantation studies support the importance of epithelial PR 
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expression for lobuloalveolar development and possibly stromal PR for ductal growth 
(Brisken et al., 1998; Humphreys et al., 1997). Two mediators of progesterone signaling are 
established in the mammary gland: the tumor necrosis factor (TNF) family member Receptor 
Activator for Nuclear Factor kappaB Ligand RANKL and the Wnt ligand Wnt4 (see Figure 
3.2.1b). Both RANKL protein and Wnt4 co-localize with PR positive luminal epithelial cells 
adjacent to proliferating cells, and their expression is regulated by progesterone (Brisken et 
al., 2000; Mulac-Jericevic et al., 2003). Moreover, deletion of RANKL or Wnt4 results in 
impaired pregnancy-induced side-branching and alveogenesis (Brisken et al., 2000; Fata et 
al., 2000), whereas their ectopic expression causes tertiary side-branching in the absence of 
pregnancy (Bradbury et al., 1995; Fernandez-Valdivia et al., 2009). Thereby, Wnt4 is thought 
to act by stimulating canonical Wnt signaling and proliferation in basal stem and/or 
progenitor cells of adult virgin mice (Rajaram and Brisken, 2009). This is discussed in more 
detail below.  
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Figure 3.2.1b Progesterone signaling cascade 
Progesterone binds to progesterone receptors (PRs) in luminal epithelial cells and activates 
the expression and secretion of the Wnt ligand Wnt4. Progesterone-stimulated Wnt4 acts on 
basal mammary stem and/or progenitor cells, promoting their proliferation and resulting in 
lobuloalveogenesis and tertiary side-branching. Fzd = Frizzled receptor 
 
Prolactin 
Final lactogenic differentiation of the mammary gland is under the control of prolactin 
(Neville et al., 2002). Transplantation experiments of prolactin receptor (PrlR) deficient 
epithelium demonstrate that prolactin signaling is required for alveolar development and 
lactogenesis during late pregnancy, but not for ductal outgrowth and side branching (Brisken 
et al., 1999). Thereby, epithelial rather than stromal PrlR expression appears central to 
mammary gland physiology, since wild type mammary epithelium transplanted into PrlR-/- 
stroma develops normally (Ormandy et al., 2003). Mechanistically, prolactin was shown to 
act via IGF-2 and cyclin D1 in the mammary gland (Brisken et al., 2002; Hovey et al., 2003).  
 
In order to elicit growth responses in the mammary gland, the hormone- and growth factor-
initiated signaling pathways must influence cell proliferation, lineage commitment and 
differentiation of specific mammary epithelial cell subtypes. The discovery of techniques to 
isolate and manipulate specific mammary epithelial cell subpopulations (see above) has 
greatly improved the understanding of the cell fate determining signaling pathways in 
postnatal mammary gland development and homeostasis.  
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3.2.2 Cell fate determining signaling pathways 
Mammary gland growth in response to hormones/growth factors and tissue homeostasis relies 
on the ability of stem and progenitor cells to self-renew and/or to differentiate (Roarty and 
Rosen, 2010). Several signaling pathways have been found to govern these processes in 
mammary stem and progenitor cells, including Wnt, Notch, TGFβ, and receptor tyrosine 
kinase (RTK) signaling.  
 
Wnt signaling 
Wingless related protein (Wnt) signaling is central to cell fate decisions and stem cell 
homeostasis in many species and organs (Munoz-Descalzo et al., 2012). The Wnt proteins 
constitute a family of 19 highly conserved secreted glycoproteins. They initiate receptor-
mediated signaling cascades, of which the Wnt/beta-catenin-dependent or ‘canonical’ 
pathway is best characterized (Angers and Moon, 2009). Canonical Wnt signaling involves 
the interaction of Wnt ligands with seven-pass-transmembrane-spanning Frizzled (Fzd) 
receptors and with co-receptors of the LDL-receptor-related protein family (Lrp5/6). Binding 
of Wnts to the receptor complex prevents destruction of β-catenin by a degradation complex 
containing glycogen synthase kinase-β (GSK-3β), axin, and adenomatous polyposis coli 
(APC). This allows β-catenin to accumulate in the nucleus and interact with the nuclear 
Lymphoid Enhancer Factor/T-Cell-Specific Transcription Factor (LEF/TCF) family of 
transcription factors, resulting in the expression of the respective target genes (Angers and 
Moon, 2009). Thereby, the identity of the target genes and thus also the effect on cell fate is 
tissue and cell type-specific (Hoppler and Kavanagh, 2007).  
 
First indications for a major cell fate determining role of Wnt signaling in the mammary 
gland came from findings of differential expression patterns of Wnt ligands at specific 
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developmental stages (Gavin and McMahon, 1992). Of the Wnt proteins expressed in the 
mammary gland, specific roles have been defined for Wnt4 and Wnt5a. Whereas Wnt5a 
appears to regulate pubertal ductal morphogenesis (Roarty and Serra, 2007), Wnt4 acts 
downstream of progesterone, initiating tertiary side-branching during adulthood and early to 
mid-pregnancy (see above). Definitive evidence for a role of Wnt/β-catenin signaling in 
mammary epithelial cell fate decisions and self-renewal properties is provided by Wnt co-
receptor Lrp5/6 knockout studies (Lindvall et al., 2006; Lindvall et al., 2009), administration 
of exogenous Wnt proteins to mammary basal stem/progenitor cells (Zeng and Nusse, 2010) 
and lineage tracing experiments for Wnt responsive mammary epithelial cells (van 
Amerongen et al., 2012): Lrp5 and Lrp6 deficient mammary glands are characterized by 
reduced side-branching (Lindvall et al., 2006; Lindvall et al., 2009), Lrp5/6 is expressed in 
the basal compartment harboring basal stem and progenitor cells, and Lrp5 expressing 
mammary cells have been demonstrated to exhibit self-renewing properties (Badders et al., 
2009). Addition of purified Wnt3a protein to isolated mammary basal stem/progenitor cells 
increases their ability to clonally expand in vitro and maintains their mammary gland 
reconstitution efficiency upon transplantation in vivo. Furthermore, basal stem/progenitor 
cells mutant for the negative-feedback regulator Axin2 and thus sensitized to Wnt signaling 
show increased capacity to form functional glands in transplantation experiments (Zeng and 
Nusse, 2010). Moreover, tracing of Axin2 reporter expressing and Wnt/β-catenin responsive 
cells reveals that Wnt/β-catenin responsive mammary cells give rise to basal and luminal 
epithelial cells in a developmental stage-dependent fashion, further supporting the notion that 
Wnt/β-catenin signaling directs cell fate of mammary stem cells (van Amerongen et al., 
2012).  
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Notch signaling 
Similar to Wnt signaling, Notch signaling is involved in many cell fate decisions during 
animal development. The Notch gene encodes a transmembrane receptor with an intracellular 
part which is cleaved off upon specific ligand binding. In mammals, four Notch receptors 
(Notch 1-4) and five transmembrane ligands (Jagged1, Jagged2, Delta-like1, Delta-like3, and 
Delta-like4) have been identified and characterized (Borggrefe and Oswald, 2009). Upon 
cleavage, the Notch intracellular domain (NICD) translocates to the nucleus and binds the 
RBP-J transcription factor as well as mastermind-like (MAML) family members of co-
activators (Petcherski and Kimble, 2000; Wu et al., 2000). The RBP-J/NICD/MAML 
complex then recruits histone acetyltransferase p300 to activate Notch target gene expression 
(Oswald et al., 2001; Saint Just Ribeiro et al., 2007; Wallberg et al., 2002).  
 
In the mammary gland, the Notch pathway regulates stem and progenitor cell activity and 
commits mammary stem cells to the luminal cell lineage both in humans and mice (Bouras et 
al., 2008; Raouf et al., 2008). Accordingly, impaired Notch signaling in basal mammary 
stem/progenitor cells stimulates stem cell renewal and expansion, whereas constitutively 
active Notch specifically targets luminal progenitor cells for proliferation (Bouras et al., 
2008). Similar studies in human bipotent progenitor cells underscore the conserved role of 
Notch in luminal cell fate commitment (Raouf et al., 2008). Interestingly, a prominent Notch 
target gene in the mammary gland is Gata3 (Bouras et al., 2008), which itself stimulates 
luminal cell differentiation (Asselin-Labat et al., 2007) and thus enforces and potentially even 
partially mediates Notch’s effect on luminal commitment in the mammary gland.  
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TGFβ signaling 
Transforming Growth Factor Beta (TGFβ) signaling has long been known to regulate cell 
proliferation, apoptosis, and differentiation during mammary gland development (McNally 
and Martin, 2011). Three isoforms of mammalian TGFβ exist, TGFβ1, TGFβ2 and TGFβ3, 
all of which bind the receptor TGFβRII which in turn recruits and activates Alk5/TGFβRI. 
Both TGFβRII and Alk5/TGFβRI are single-pass transmembrane serine threonine kinases 
and upon ligand binding, they phosphorylate downstream effectors, including SMAD 
members (Dunphy et al., 2011). Phosphorylated SMAD complexes subsequently move to the 
nucleus to regulate gene transcription. In the mammary epithelium, all isoforms of TGFβ are 
expressed at moderate levels in nulliparous mice with TGFβ2 and TGFβ3 being highly 
expressed during pregnancy and early involution (Faure et al., 2000; Nguyen and Pollard, 
2000; Robinson et al., 1991). Experiments using slow-release pellets of TGFβ1 (Daniel et al., 
1989; Silberstein and Daniel, 1987) and studies involving targeted dominant-negative 
TGFβIIR (Gorska et al., 2003; Joseph et al., 1999) or overexpressed TGFβ3 (Nguyen and 
Pollard, 2000) demonstrate that TGFβ acts to confine mammary epithelial cell expansion by 
inhibiting cell proliferation and inducing apoptosis. This conclusion is underlined by findings 
in TGFβ1+/- transgenic mice, which have < 10% wild-type TGFβ1 levels and exhibit 
accelerated ductal growth and alveogenesis during puberty (Ewan et al., 2002b). Thereby, 
active TGFβ is confined to the luminal compartment (Fleisch et al., 2006), yet the inhibitory 
effect of TGFβ1 on cell proliferation extends to basal stem or progenitor cells. As a mediator 
for the inhibitory effect of TGFβ1, the non-canonical Wnt ligand Wnt5a was identified 
(Roarty and Serra, 2007), exemplifying also the interplay between the different cell fate 
determining pathways.  
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RTK signaling 
The superfamily of receptor tyrosine kinases (RTK) comprises 19 subfamilies, of which the 
epidermal growth factor receptor (EGFR) or ErbB family, the fibroblast growth factor 
receptor (FGFR) and the insulin-like growth factors (IGFs) and their receptors have 
established roles in normal mammary gland development and mammary epithelial cell fate 
determination (Hynes and Watson, 2010). The ErbB family of RTKs includes EGFR 
(ErbB1), ErbB2, ErbB3, and ErbB4. Ligand binding causes homo- or heterodimerization of 
the receptors, thereby activating their cytoplasmic kinase domains and initiating signaling 
(Hynes and Watson, 2010). In the mammary gland, multiple EGF-family ligands and all of 
the ErbB receptors are expressed during ductal morphogenesis, pregnancy-induced 
alveogenesis, and during lactation (Schroeder and Lee, 1998). Transgenic mice with impaired 
EGFR exhibit reduced ductal outgrowth (Sebastian et al., 1998), whereas pellets releasing 
EGF can rescue ductal development in ovariectomized mice (Coleman et al., 1988). Further 
studies involving knockout mice and transplantation procedures support a crucial role of 
stromal EGFR in mediating the effects of estrogen, downstream of estrogen-induced 
amphiregulin release from mammary epithelial luminal cells and upstream of FGF2 and 
FGF7 secretion (Sternlicht et al., 2005) (see Figure 3.2.1a).  
 
The FGF family includes 22 ligands and four receptors, FGFR1-4. During ductal 
morphogenesis, multiple FGFs, including FGF2 and FGF7, as well as FGFR1 and FGFR2 are 
expressed (Hynes and Watson, 2010; Schwertfeger, 2009). FGFR2 signaling is important for 
embryonic mammary placode and bud formation, and mice deficient in the isoform FGFR2b 
fail to develop mammary placodes 1, 2, 3 and 5 (Mailleux et al., 2002). The requirement for 
FGFR signaling in mammary stem cell maintenance postnatally is supported by the 
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competitive disadvantage of mammary epithelial cells with deleted FGFR1 and FGFR2 in 
transplantation experiments (Pond et al., 2013).  
 
Amongst the insulin-like growth factors (IGFs), IGF1 has an important role downstream of 
GH whereas IGF2 is expressed in response to prolactin signaling and acts to induce cyclinD1 
expression (see above) (Brisken et al., 2002). Notably, IGF1 signaling in the mammary gland 
is fine-tuned by the secretion of IGF-binding proteins by mammary epithelial and stromal 
cells (Flint et al., 2008).  
 
Apart from these main cell fate determining pathways in the mammary gland known to date, 
several accessory signaling pathways are believed to have integrative roles. Hedgehog 
signaling is one example (Sternlicht, 2006). However, the details of many interactions remain 
to be determined and are under current investigation by several research groups.  
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Figure 3.2.2 Overview of hormone, growth factor and cell fate determining signaling 
pathways in mammary gland development 
Schematic illustration of mammary gland developmental stages and the corresponding critical 
signaling cascades. 
 
 
3.3 Breast cancer 
3.3.1 Pathogenesis and subtypes of breast cancer 
Aberrant normal mammary gland growth and homeostasis may lead to cancer. Breast tumors 
arise from mammary epithelial cells (Sims et al., 2007) and are thought to progress from flat 
epithelial atypia (FEA), via atypical ductal hyperplasia (ADH) and ductal carcinoma in situ 
(DCIS) to invasive ductal carcinoma (IDC) (Bombonati and Sgroi, 2011). Cause of death is 
usually metastasis of malignant tumor cells to distant organs such as bone, lung, liver, and 
brain (Nguyen et al., 2009). Clinically, breast cancers are classified according to tumor size, 
histological grade, node status, and expression of estrogen receptor (ER), progesterone 
receptor (PR) and epidermal growth factor receptor 2 (HER2/ErbB2) (Di Cosimo and 
Baselga, 2010; Sotiriou and Pusztai, 2009). Apart from this conventional classification 
method which directs current treatment strategies, the development of large scale molecular 
profiling techniques has led to the identification of distinct breast cancer subtypes, which 
vary according to their intrinsic aggressiveness and their prognosis (Morris and Carey, 2007). 
Based on global gene expression analyses, the following subtypes of breast cancer are 
distinguished: luminal A, luminal B, HER2- or ErbB2-enriched, basal-like, normal-like and 
claudin-low (Herschkowitz et al., 2007; Perou and Borresen-Dale, 2011; Perou et al., 2000; 
Prat et al., 2010; Sorlie et al., 2001). On the basis of copy number variants and single 
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nucleotide polymorphisms, further breast cancer subgroups are defined, which yet remain to 
be characterized in detail (Curtis et al., 2012).  
 
The most frequently diagnosed breast cancers are hormone receptor-positive tumors and fall 
into the luminal A or the luminal B breast cancer subtypes. They are characterized by a gene 
expression profile similar to luminal mammary epithelial cells (Perou et al., 2000) and are 
often low-grade (Perou and Borresen-Dale, 2011). Luminal A tumors comprise 40-50% of all 
breast cancers (Carey et al., 2006; Millikan et al., 2008; Morris et al., 2007) and exhibit high 
expression of ER and ER-regulated genes (including PR) with low expression of proliferation 
markers such as Ki-67 (Hu et al., 2006b; Sorlie et al., 2001; Sorlie et al., 2003). They are 
associated with responsiveness to hormonal therapy and good prognosis (Fan et al., 2006; Loi 
et al., 2007; Sotiriou et al., 2003). In contrast, luminal B tumors (accounting for 
approximately 10% of all breast cancers), exhibit lower expression of ER and ER-regulated 
genes (Perou and Borresen-Dale, 2011), are much more proliferative and less responsive to 
hormonal therapy (Sims et al., 2007; Sotiriou and Pusztai, 2009).  
 
The HER2- or ErbB2-enriched breast cancer subtype represents 10-25% of all breast cancers 
and is characterized by increased HER2/ErbB2 expression (Berger et al., 1988; Carey et al., 
2006; Slamon et al., 1987; van de Vijver et al., 1987). Further features of this subtype 
comprise low expression of basal-like and/or hormone receptor-regulated genes, high 
expression of proliferation markers and high incidence (> 40%) of mutations in p53, a key 
mediator of cellular response to DNA damage (Perou and Borresen-Dale, 2011). HER2- or 
ErbB2-enriched breast cancers are typically high-grade tumors, and before the era of HER2-
targeted therapies, this subtype was associated with poor prognosis (Parker et al., 2009; Sorlie 
et al., 2001).  
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Basal-like tumors tend to lack HER2/ErbB2, ER, PR expression and represent the major part 
of what is clinically known as “triple-negative” cancers (Di Cosimo and Baselga, 2010; Perou 
and Borresen-Dale, 2011). They comprise 15-20% of breast cancer cases and are 
characterized by aggressive clinical behavior and high incidence of metastasis (Di Cosimo 
and Baselga, 2010). Apart from the expression of basal epithelial markers (cytokeratin 5, 6, 
14, 17, c-kit, vimentin, p-cadherin etc.) which accounts for their name, basal-like tumors 
exhibit a strong “proliferation signature” and may be marked by a high p53 mutation rate (> 
50%) and aberrant BRCA1 activity, a gene essential for proper DNA repair and chromosomal 
stability (Perou and Borresen-Dale, 2011; Turner et al., 2007). In line with the latter are 
findings of most BRCA1-associated tumors being triple negative and basal-like (Anders and 
Carey, 2008). Although the subtype of triple negative and basal-like breast cancers often 
responds well to chemotherapy, the overall prognosis is poor (Di Cosimo and Baselga, 2010; 
Rouzier et al., 2005; Sims et al., 2007).  
 
Normal-like breast cancers resemble the normal breast in their gene expression. They are 
poorly characterized, but exhibit a better prognosis than basal-like cancers despite their 
failure to respond to neoadjuvant chemotherapy (Fan et al., 2006; Rakha et al., 2008; Rouzier 
et al., 2005; Sorlie et al., 2001).  
 
The claudin-low subtype of breast tumors has been identified more recently (Herschkowitz et 
al., 2007) and is characterized by reduced expression of cell adhesion and tight junction genes 
and by increased expression of mesenchymal genes (Perou and Borresen-Dale, 2011). Such 
decreased epithelial and increased mesenchymal features are typical for normal mammary 
stem cells. This finding was influential for one of the current hypotheses regarding the cells 
of origin of specific breast cancer subtypes.  
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Comparing the gene expression profiles of normal FACS-sorted mammary cell 
subpopulations with breast cancer subtypes showed similarities between basal 
stem/progenitor cells and claudin-low/normal-like cancers, between luminal progenitor cells 
and basal-like tumors, and between differentiated luminal cells and luminal A/B cancers (Lim 
et al., 2009) (see Figure 3.3.1). However, whilst deductions from such correlations on 
potential cells of origin are attractive, direct tumorigenic capacity needs to be demonstrated in 
lineage tracing or clonality experiments. An alternative hypothesis for cells of cancer origin is 
based on specific mammary cell subpopulations showing differentiation plasticity during 
tumorigenesis. According to this theory, the gene expression profiles of the breast cancer 
subtypes do not reflect the features of their actual cells of origin (Visvader, 2009).  
 
 
 
Figure 3.3.1 Breast cancer subtypes and potential cells of origin 
Gene expression comparisons suggest a relationship of breast cancer subtypes and cells of 
origins as depicted with full arrows. In contrast, hypotheses based on mammary cell plasticity 
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and differentiation promote mechanistic models where tumors arise from stem or progenitor 
cells (dotted arrows).  
 
 
3.3.2 Cell fate determining signaling pathways and breast carcinogenesis 
Amongst the main cell fate determining signaling pathways identified in the mammary gland, 
aberrantly increased Wnt signaling plays a central role in mammary oncogenesis (Visvader, 
2009). Transgenes encoding components of the Wnt signaling pathway target 
undifferentiated mammary progenitor cells for tumorigenesis (Li et al., 2003; Liu et al., 2004; 
Teuliere et al., 2005) and render them resistant to radiation therapy (Woodward et al., 2007). 
Moreover, the Wnt/β-catenin pathway is activated following knockdown of the tumor 
suppressor gene PTEN in human breast cells (Korkaya et al., 2009), and most invasive breast 
carcinomas exhibit downregulation of the secreted Wnt inhibitor Secreted Frizzled-Related 
Protein1 (Sfrp1) (Roarty and Rosen, 2010; Ugolini et al., 2001), further underscoring the 
connection between Wnt signaling and breast carcinogenesis.  
 
Similar to increased Wnt signaling, elevated and inappropriate RTK signaling in the 
mammary gland is strongly linked to oncogenesis. ErbB2 or HER2 overexpression accounts 
for up to 25% of breast cancer cases (see above), transgenic mice overexpressing EGFR 
develop hyperplasias and mammary cancers (Brandt et al., 2000), EGFR is expressed in 30-
60% of basal-like breast cancers (Reis-Filho and Tutt, 2008; Thike et al., 2010) and clinical 
trials with EGFR inhibitors are ongoing (ClinicalTrial.gov). Apart from the key role of EGFR 
signaling in breast carcinogenesis, FGF and IGF-1 signaling are also implicated in tumor 
initiation and progression (reviewed in (Hynes and Watson, 2010)).  
 
  Introduction   
 
 
30 
 
Unlike Wnt and RTK signaling, which both have clear tumor-promoting effects in the 
mammary gland, the roles of Notch and TGFβ signaling are equivocal, and oncogenic as well 
as tumor-suppressing properties are observed for both pathways. Study results regarding 
altered Notch signaling in breast tumor tissue and its prognostic value are ambiguous 
(Dickson et al., 2007; Han et al., 2011; Lee et al., 2007; Li et al., 2010; Mittal et al., 2009; 
Zardawi et al., 2010). In line with a tumor-suppressive role of Notch signaling, high Notch2 
mRNA expression is associated with good clinical outcomes (Parr et al., 2004) and ectopic 
expression of the active intracellular domain of Notch2 (N2ICD) has been demonstrated to 
reduce growth and enhance apoptosis of basal-like breast cancer cells (O'Neill et al., 2007). 
Interestingly, recent evidence suggests that the tumor-suppressive role of Notch signaling 
may in part function by counteracting WNT/β-catenin signaling (Kim et al., 2012). In support 
of an oncogenic role, positive associations are observed for Notch2 and HER2 expression in 
invasive human breast cancers (Florena et al., 2007). Moreover, overexpression of the active 
intracellular domain of Notch4 (N4ICD) increases cellular proliferation in the same basal-like 
breast cancer cells which are inhibited by N2ICD (O'Neill et al., 2007), transgenic mice 
expressing constitutively active N1ICD or N3ICD in mammary epithelium form mammary 
tumors (Hu et al., 2006a), and Notch1 inhibition results in mammary tumor regression in 
transgenic mouse models (Simmons et al., 2012). Together, the data suggest cell type- and 
paralog-specific effects of Notch signaling in carcinogenesis, but more studies are warranted 
to define the exact roles of distinct Notch paralogs on specific mammary epithelial cell 
subtypes.  
 
Like Notch signaling, TGFβ signaling also has paradoxical roles in mammary tumorigenesis. 
TGFβ regulates tumor proliferation by mediating cell cycle arrest (Dunphy et al., 2011; Ewan 
et al., 2005). It inhibits telomerase activity (Li et al., 2007; Li and Liu, 2007) and induces 
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apoptosis (Bierie et al., 2009; Ewan et al., 2002a), thereby suppressing tumorigenesis. In 
contrast, TGFβ promotes epithelial-to-mesenchymal transition (EMT) and induces metastatic 
and invasive properties in tumor cells resistant to its tumor-suppressing roles (Dumont and 
Arteaga, 2000; Muraoka-Cook et al., 2005).  
 
 
3.4 Pregnancy and risk of breast cancer 
3.4.1 Epidemiological data in humans and experimental studies in rodents 
An extensive body of epidemiological studies has established a strong and life-long breast 
cancer protective effect of early full-term pregnancy in humans (Albrektsen et al., 2005; 
Kelsey et al., 1993; MacMahon et al., 1970; McPherson et al., 2000). This protective effect is 
at least 50% with a pregnancy occurring before the age of 20 years. Interestingly, pregnancy-
induced breast cancer protection is negligible with first full-term pregnancies at ages between 
30 and 34 and is even reversed to an overall increased risk of developing mammary tumors 
with first pregnancies after the age of 35 years (MacMahon et al., 1970; Trichopoulos et al., 
1983). Apart from early age at first pregnancy, multiple pregnancies and extensive 
breastfeeding also decrease a woman’s breast cancer risk, although to a relatively small 
degree: the time of breastfeeding is inversely associated with breast carcinoma and every 
additional pregnancy confers a further 10-13% of protection against breast cancer (Lambe et 
al., 1996; Ursin et al., 2004). Importantly, before the protective effect of pregnancy becomes 
apparent, there is an initial increase in breast cancer risk immediately after parturition in 
women over 25 years (Albrektsen et al., 2005). This transient and pregnancy-associated 
elevation in breast cancer risk is most pronounced in women older than 30 years (Albrektsen 
et al., 2005; Lambe et al., 1994; Schedin, 2006) and may account at least in part for the 
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overall increase in breast cancer risk observed in women older than 35 years at first full-term 
pregnancy.  
 
 
 
Figure 3.4.1 Effect of pregnancy and age at first birth on breast cancer risk  
Schematic illustration of the epidemiologic study results from the last decades demonstrating 
that (1) early pregnancy decreases the breast cancer risk in the long-term, (2) the breast 
cancer protective effect of pregnancy is greater the earlier the pregnancy has occurred, (3) 
pregnancy leads to a transient increase in breast cancer risk following parturition, and (4) 
pregnancy-associated increase in breast cancer risk becomes more pronounced with late age 
at pregnancy.  
 
Further analysis of the epidemiologic data for breast cancer subtypes shows that parity 
specifically protects against ER+/PR+ breast cancer. A meta-analysis on two cohort, six 
population-based case-control and two hospital-based case control studies affirmed that each 
birth reduces the risk of ER+/PR+ breast cancer by 11% and that women in the highest age at 
first birth category have a 27% higher life-time risk of developing ER+/PR+ tumors 
compared to women in the youngest age at first birth category. In contrast, neither parity 
  Introduction   
 
 
33 
 
itself nor age at first birth affects the risk of ER-/PR- breast cancers (Ma et al., 2006). In line 
with this conclusion, a recent analysis pooling data from 34 studies and including 35,568 
invasive breast cancer case patients found clear inverse associations between parity/early age 
at first birth and ER+ tumors (Yang et al., 2011). Regarding breastfeeding and tumor 
subtypes, data is less definitive, but recent results point towards a protective effect of 
breastfeeding mainly against luminal breast cancers (Turkoz et al., 2012). With respect to the 
familial breast cancers BRCA1 and BRCA2, study results are equivocal, but the majority of 
large studies in Western Europe demonstrate a protective effect of parity against both 
BRCA1 and BRCA2 associated breast cancers (Andrieu et al., 2006; Antoniou et al., 2006; 
Milne et al., 2010). Given that BRCA1 tumors tend to be ER- (see above and (Foulkes et al., 
2004; Musolino et al., 2007), this finding may seem surprising. However, BRCA1 carriers are 
protected against breast cancer by oophorectomy (Eisen et al., 2005; Rebbeck et al., 1999), 
suggesting an indirect hormone-dependency of these tumors which may account for the 
protective effect of an early pregnancy.  
 
Parity-induced protection against breast cancer is well-established not only in humans, but 
also in experimental rodent models. In rats or mice, high incidence of mammary cancers is 
observed in virgin animals after carcinogen administration, but the same carcinogens fail to 
induce tumors when given to rats or mice after a full-term pregnancy in greater than 75% of 
cases (Moon, 1969; Russo and Russo, 1980; Sinha et al., 1988; Thordarson et al., 1995; Yang 
et al., 1999). Moreover, hormonal mimicry of pregnancy, by treatment with estrogen and 
progesterone or human chorionic gonadotropin for at least 21 days, has proven equally 
effective as early full-term pregnancy for preventing mammary cancers in carcinogen-treated 
rodents (Grubbs et al., 1985; Guzman et al., 1999; Rajkumar et al., 2001; Russo et al., 1990). 
More recently, such hormone treatment has been shown to prevent mammary tumorigenesis 
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in two different genetically engineered mouse models of breast cancer (the p53-null 
mammary transplant model and the Her2/Neu transgenic mouse model) (Rajkumar et al., 
2007).  
 
With respect to the length of pregnancy required to confer breast cancer protection, limited 
studies in humans suggest that interrupted pregnancies neither raise nor reduce the risk of 
mammary tumorigenesis (Erlandsson et al., 2003; Goldacre et al., 2001; Henderson et al., 
2008; Melbye et al., 1997; Michels et al., 2007), whereas two rodent studies gave ambiguous 
results: One showed that pregnancy terminated at day 5, 10, or 15 leads to an intermediate 
mammary cancer incidence following carcinogen administration of 48, 50, and 45% as 
compared to 70-88% in virgins and 14% in parous control mice (Sinha et al., 1988). The 
other study observed no protective effect for pregnancy interrupted at day 12 (Russo and 
Russo, 1980). The divergent results may be explained by differences in the size of the animal 
groups used and thus differences in the statistical powers, and/or by the specific time points 
of carcinogen treatment (21 days versus 15 days after end of hormone treatment). Further 
experiments are needed and may provide hints regarding the mechanism underlying the 
protective role of parity against breast cancer.  
 
3.4.2 Hypothetical mechanisms of breast cancer protective effect 
Although the breast cancer protective effect of an early full-term pregnancy or its hormonal 
mimicry has been known for decades, the cellular and molecular mechanisms underlying this 
phenomenon remain unclear. The prevailing hypotheses involve two cell non-autonomous 
and three cell autonomous mechanisms. Thereby, the individual theories are not mutually 
exclusive, and a combination of several processes is probably required to bring about the full 
protective effect.  
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Hypotheses based on cell non-autonomous mechanisms specify potential persistent changes 
in circulating hormones and/or changes in the stromal composition of the mammary gland as 
crucial parity-induced alterations resulting in decreased propensity for breast tumorigenesis 
(Medina, 2005; Schedin et al., 2004; Thordarson et al., 1995). Due to diurnal, cyclical, and 
age-dependent changes, studies on hormone levels require especially large cohorts in humans 
and/or good control measures in rodents. Whereas no clear and reproducible changes in 
estrogen and progesterone hormone levels are reported after pregnancy, prolactin (PRL) 
levels seem decreased at least transiently in parous women, a finding reproduced in some but 
not all rodent studies (Bernstein et al., 1985; Bridges and Byrnes, 2006; Bridges et al., 1993; 
Dorgan et al., 1995; Eliassen et al., 2007; Ingram et al., 1990; Kwa et al., 1981; Musey et al., 
1987; Thordarson et al., 1995). Moreover, the growth hormone (GH) – insulin growth factor 
1 (IGF-1) axis appears persistently suppressed after pregnancy in rats (Thordarson et al., 
1995). Interestingly, diminished PRL and GH secretion induces regression of mammary 
tumors (Rose et al., 1983), and virgin GH-deficient rats are refractory to mammary 
carcinogenesis (Swanson and Unterman, 2002), whereas increased levels of PRL and GH or 
IGF-1 are associated with elevated incidence of mammary carcinogenesis in several studies 
(Harvey, 2012; Ingram et al., 1990; Thordarson et al., 2004). Such findings suggest a possible 
role of prolactin and GH in parity-induced breast cancer protection. Furthermore, long-lasting 
alterations of the mammary stroma extracellular matrix composition (ECM) and its signaling 
have been observed in rodent mammary glands (Schedin et al., 2004). Notably, the matrix of 
parous animals restricts glandular morphogenesis in 3-D in vitro cultures, thus suggesting the 
presence of growth – and possibly also tumor – suppressing factors in the ECM of parous 
individuals (Schedin et al., 2004).  
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With respect to cell autonomous processes, hypotheses for parity-induced breast cancer 
protection are based on potential changes in differentiation state and hormone responsiveness 
of the entire mammary gland or alterations in cell fates of specific mammary epithelial cell 
subpopulations (Britt et al., 2007; Medina, 2005; Russo and Russo, 2011). Regarding 
mammary gland differentiation, it was postulated that pregnancy- or pregnancy hormones-
induced terminal differentiation of the mammary gland removes cancer-susceptible cells, 
thereby decreasing the gland’s propensity to form tumors (Russo and Russo, 1997; Russo et 
al., 1982). This hypothesis is supported by studies examining genome-wide expression 
profiles of entire lobular breast tissues of women or entire mammary glands of rodents, which 
demonstrate a clear increase in the expression of differentiation genes in breast tissues or 
mammary glands from parous individuals (Blakely et al., 2006; D'Cruz et al., 2002; Russo et 
al., 2008). However, although attractive, mammary gland differentiation per se cannot 
explain all observed aspects, since neither placental lactogen nor perphenazine, both of which 
cause the mammary gland to differentiate, protect against mammary tumorigenesis (Guzman 
et al., 1999; Medina, 2005). Furthermore, pregnancy or its hormonal mimicry does not lead to 
persistent morphologically distinguishable differentiated cells (Sinha et al., 1988).  
 
Regarding the responsiveness of the mammary gland to reproductive hormones, it was 
suggested that a decrease in the ability of the mammary gland to sense estrogen might 
underlie the breast cancer’s protective effect of an early pregnancy (Britt et al., 2007). This 
theory is consistent with the roles of estrogen and progesterone in cancer: Numerous studies 
relate breast cancer risk to cumulative dosage of reproductive hormones, and early menarche, 
late menopause, and hormone replacement therapy all increase the life-time exposure to 
estrogen and progesterone and similarly raise the risk of breast tumorigenesis (1997; 2012; 
Beral, 2003; Heiss et al., 2008; Henderson et al., 1988; Ritte et al., 2012). In contrast, 
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decreasing hormone exposure by oophorectomy reduces mammary cancer risk (Schneider et 
al., 1969). Interestingly, ERα-positive estrogen sensing cells are known to increase with age 
and cancerous progression (Shoker et al., 1999), thereby underscoring a possible direct 
relationship between mammary gland hormone responsiveness and breast cancer risk.  
 
The most hotly debated theory for the breast cancer protective effect of an early pregnancy 
proposes a parity-induced change in the cell fate of specific mammary epithelial cell 
subpopulations. According to this hypothesis, the hormonal environment of pregnancy alters 
the developmental fate of a subpopulation of mammary epithelial cells by inducing persistent 
changes in signaling pathways, growth factors and/or other regulatory molecules. These 
differences reduce the cell subpopulation’s proliferation potential and render it relatively 
resistant to tumorigenesis, whilst the capacity to form complete differentiated lobular 
structures during a next pregnancy is maintained (Medina, 2005). In line with the cell fate 
theory, mammary cells from hormone-treated animals demonstrate a block in carcinogen-
induced proliferation (Sivaraman et al., 1998). Furthermore, a new mammary epithelial cell 
population, termed parity-identified mammary epithelial cells (PI-MECs) was found to 
originate from differentiating cells during pregnancy (Wagner et al., 2002). These cells are 
pluripotent and can contribute to mammary outgrowths in transplantation experiments, thus 
exhibiting properties of stem and/or progenitor cells (Boulanger et al., 2005). Conceivably, a 
molecular switch in mammary stem cells may explain the breast cancer protective effect of 
early pregnancy (Russo and Russo, 2011), since the longevity and self-renewing property of 
stem cells make this population a prime target for transformation and tumorigenesis (Lindvall 
et al., 2007; Wagner and Smith, 2005). Notably, two studies in mice have addressed the issue 
of stem cell numbers in parous compared to virgin mammary glands by transplanting total 
mammary (epithelial) cells, but reported conflicting results (Britt et al., 2009; Siwko et al., 
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2008). Despite all these indications, the cell fate hypothesis has until now never been 
addressed directly, for example by examining the individual mammary epithelial cell 
subpopulations in parous and virgin tissue side by side, thereby eliminating the masking 
effects of other cell types.  
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4. AIMS OF THE WORK/SCOPE OF THESIS 
In this study we tested the possibility that early pregnancy induces cell autonomous processes 
that can potentially explain the observed breast cancer protective effect of early parity in 
humans and rodents. Notably, we investigated whether early pregnancy changes the 
molecular properties (“cell fates”) of specific mammary epithelial cell subtypes, and whether 
such changes can be explained by alterations of the hormone responsiveness of the mammary 
gland. Specifically, the following questions were addressed:  
 
1) Does early parity induce specific changes in gene expression and signaling pathways 
in one or several mammary epithelial cell subpopulations? 
2) Does early parity affect the in vitro proliferation/differentiation potential of distinct 
mammary epithelial cell subtypes and the in vivo reconstitution capacity of isolated basal 
mammary stem/progenitor cells? 
3) Can changes in hormone (e.g. estrogen, progesterone) responsiveness of the 
mammary gland explain potentially altered cell fates after early pregnancy? 
 
The studies were performed in a previously validated mouse model, which allowed precise 
control for reproductive factors and their timing and provided a genetically homogenous 
background. 
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5. RESULTS  
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5.1 Abstract 
Introduction: Early pregnancy has a strong protective effect against breast cancer in humans 
and rodents, but the underlying mechanism is unknown. Because breast cancers are thought 
to arise from specific cell subpopulations of mammary epithelia, we studied the effect of 
parity on the transcriptome and the differentiation/proliferation potential of specific luminal 
and basal mammary cells in mice. 
Methods: Mammary epithelial cell subpopulations (luminal Sca1-, luminal Sca1+, basal 
stem/progenitor, and basal myoepithelial cells) were isolated by flow cytometry from parous 
and age-matched virgin mice and examined by using a combination of unbiased genomics, 
bioinformatics, in vitro colony formation, and in vivo limiting dilution transplantation assays. 
Specific findings were further investigated with immunohistochemistry in entire glands of 
parous and age-matched virgin mice. 
Results: Transcriptome analysis revealed an upregulation of differentiation genes and a 
marked decrease in the Wnt/Notch signaling ratio in basal stem/progenitor cells of parous 
mice. Separate bioinformatics analyses showed reduced activity for the canonical Wnt 
transcription factor LEF1/TCF7 and increased activity for the Wnt repressor TCF3. This 
finding was specific for basal stem/progenitor cells and was associated with downregulation 
of potentially carcinogenic pathways and a reduction in the proliferation potential of this cell 
subpopulation in vitro and in vivo. As a possible mechanism for decreased Wnt signaling in 
basal stem/progenitor cells, we found a more than threefold reduction in the expression of the 
secreted Wnt ligand Wnt4 in total mammary cells from parous mice, which corresponded to a 
similar decrease in the proportion of Wnt4-secreting and estrogen/progesterone receptor-
positive cells. Because recombinant Wnt4 rescued the proliferation defect of basal 
stem/progenitor cells in vitro, reduced Wnt4 secretion appears to be causally related to parity-
induced alterations of basal stem/progenitor cell properties in mice. 
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Conclusions: By revealing that parity induces differentiation and downregulates the 
Wnt/Notch signaling ratio and the in vitro and in vivo proliferation potential of basal 
stem/progenitor cells in mice, our study sheds light on the long-term consequences of an 
early pregnancy. Furthermore, it opens the door to future studies assessing whether inhibitors 
of the Wnt pathway may be used to mimic the parity-induced protective effect against breast 
cancer. 
©2013  Meier‐Abt  et  al.;  licensee  BioMed  Central  Ltd.  This  is  an  open  access  article 
distributed  under  the  terms  of  the  Creative  Commons  Attribution  License 
(http://creativecommons.org/licenses/by/2.0),  which  permits  unrestricted  use, 
distribution,  and  reproduction  in  any  medium,  provided  the  original  work  is  properly 
cited. 
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5.2 Introduction 
Pregnancy is the most significant modifiable factor known for breast cancer risk in women. 
Although an initial increase in risk occurs immediately after parturition in women older than 
25 years, the overall lifetime risk of breast cancer decreases after pregnancy [1,2]. This 
protective effect is >50% if a full-term pregnancy has occurred before the age of 20 years [1]. 
Similarly, pregnancy and pregnancy-mimicking hormones have a strong protective effect 
against mammary tumors in rodents. This is true both for carcinogen-induced mammary 
tumors [3] and for genetically engineered mouse models of breast cancer [4]. 
 
The cellular and molecular mechanisms underlying the breast cancer-protective effect of 
early pregnancy remain unclear. Frequently raised hypotheses involve cell non-autonomous 
mechanisms such as systemic changes in circulating hormones and/or changes in the stromal 
composition of the mammary gland [5,6], and cell autonomous processes such as changes in 
the differentiation state of mammary epithelial cells [7]. Furthermore, numerous parity-
induced changes in gene expression have been identified in genome-wide expression profiles 
of entire lobular breast tissues of women or entire mammary glands of rats and mice [8-10]. 
However, it is not known to what extent these tissue studies reflect alterations in gene-
expression profiles of distinct mammary epithelial cell subpopulations. Hence, given that 
breast cancers arise from specific subpopulations of mammary epithelial cells [11], 
investigations of early parity-induced gene-expression changes in distinct mammary 
epithelial cell subpopulations are warranted. 
 
The mammary epithelium is hierarchically organized into differentiated luminal and basal 
(myoepithelial) cells, luminal and basal progenitor cells, and mammary stem cells [12,13]. 
Whereas the latter were originally thought to lie exclusively in the basal compartment and to 
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be multipotent (able to form both luminal and basal epithelial cells), recent lineage-tracing 
experiments indicated the existence of unipotent basal and luminal mammary stem cells and 
identified multipotent mammary stem cells solely in the embryonic and possibly in the 
pregnant gland [14,15]. Distinct mammary epithelial cell subpopulations, including luminal 
progenitor and basal stem/progenitor cells can be isolated with fluorescence-activated cell 
sorting (FACS) by using specific cell-surface markers from both parous and virgin mice [16-
21]. Whereas progenitor cells in general can be characterized in vitro by their colony-forming 
potential [16,22,23], the basal stem/progenitor cell subpopulation has the additional capacity 
to repopulate deepithelialized mouse mammary fat pads in vivo [16-18]. Although previous 
studies in total mammary epithelial cells indicated either no change or a decrease in the 
mammary repopulating capacity after parity [20,21], the consequences of parity on the 
transcriptome and functionality of specific mammary epithelial cell subpopulations have not 
been investigated. 
 
Therefore, we examined in this study whether pregnancy alters the gene-expression profiles 
(“gene signature”) and the differentiation/proliferation potentials of the various mammary 
epithelial cell subpopulations. The results indicate that early parity decreases Wnt4 expression 
in luminal epithelial cells, leading to a reduction in the Wnt/Notch signaling ratio specifically 
in basal stem/progenitor cells. As expected, the decrease in the Wnt/Notch signaling ratio is 
associated with a concomitant strong prodifferentiation and antiproliferation phenotype in 
basal stem/progenitor cells. Because a decrease in Wnt signaling is known to have an 
anticarcinogenic effect [24,25], the findings support the hypothesis that a reduction in the 
Wnt/Notch signaling ratio in basal mammary stem/progenitor cells plays a role in the 
mitigating effect of early pregnancy on breast tumorigenesis. 
  
  Results   
 
 
46 
 
5.3 Methods 
5.3.1 Animals and animal experimentation 
All experiments were conducted in genetically homogenous FVB/NHanHsd mice purchased 
from Harlan Laboratories. The mice were bred and maintained in the animal facility of the 
Friedrich Miescher Institute, according to the Swiss guidelines on animal experimentation. 
All experiments were performed under permit 2159-2, in accordance with the animal-welfare 
ordinance and approved by the cantonal veterinary office of Basel Stadt, Switzerland. For the 
early-pregnancy protocol, mice were time-mated when 42 days old and allowed to lactate for 
21 days. The postweaning period until cell harvest was 40 days, unless stated otherwise. To 
control for the estrus cycle in the transcriptome analyses, at least five mice were grouped for 
gland harvesting. For immunohistochemical analyses and determination of blood 
progesterone levels, mice in estrus were used, as assessed by the presence of a vaginal plug 
after an overnight mating. Age-matched virgin control mice were maintained under the same 
conditions as parous mice. 
 
5.3.2 Whole mounts 
Whole mounts were prepared by fixing the glands on glass slides with methacarnoy solution 
(60% methanol, 30% chloroform, 10% glacial acetic acid) for 4 hours at room temperature. 
The mounts were hydrated by sequential incubation in ethanol solutions of decreasing 
concentration: 100%, (overnight), 70%, 50%, and 30% (15 minutes each), distilled water (2 × 
5 minutes), and stained overnight with an aqueous solution of 2% carmine (Sigma, Buchs, 
Switzerland) and 5% aluminum potassium sulfate (Sigma, Buchs, Switzerland). The mounts 
were dehydrated in ethanol solutions (70%, 90%, 95%, and 2 × 100%, for 15 minutes each) 
and cleared with xylene overnight. Images were captured with an Epson Expression 1600 Pro 
scanner. 
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5.3.3 Mammary cell preparation 
The fourth mammary glands from virgin and parous mice were collected after lymph node 
removal and pooled. Mammary epithelial organoids were prepared as described [26]. 
Adipocytes were removed by repeated centrifugations (300 g). Red blood cells (RBCs) were 
eliminated by incubation with 8.3 g/L ammonium chloride (pH 7.5) for 5 minutes. The 
number of fibroblasts in gland extracts was reduced by their attachment to polystyrene cell-
culture flasks (Corning, Buchs, Switzerland) during a 45-minute incubation step in Dulbecco 
modified Eagle medium (Invitrogen, Zug, Switzerland) with 10% FCS (Sigma, Buchs, 
Switzerland) at 37°C/5% CO2 [26]. The epithelial organoids were directly processed to 
single-cell suspensions by digestion in Hyclone HyQTase (ThermoScientific, Lausanne, 
Switzerland) with gentle pipetting for 15 minutes at 37°C. The cell suspension was filtered 
through a 40-µm cell strainer (BD Falcon, Basel, Switzerland), and the final cell suspension 
pelleted at 650 g for 4 minutes. 
 
5.3.4 Cell labeling and flow cytometry 
Cells were labeled as previously described [26] by using the antibodies PE-Cy7-CD45 (1:33), 
FITC-CD24 (1:40), PE-CD49f (1:40), and APC-Sca1 (1:40). Detailed antibody information 
is given later. DAPI (0.2%, Invitrogen, Zug, Switzerland) was added 10 minutes before cell 
sorting (1:250). FACS was carried out on a MoFlo cell sorter (Becton Dickinson, Basel, 
Switzerland). Cells were gated based on their forward- and side-scatter profiles (FS Area and 
SS Area). A time-of-flight approach (pulse width) was used to exclude doublets and higher-
order cell clumps. Dead cells (DAPI bright) and immune cells (CD45+) were gated out (see 
Additional file 1). The gate for basal stem/progenitor cells was set at the top 5% of CD49f-
expressing cells, as described [19,21] (see Figure 1). Routine examination of the sorted 
mammary epithelial cell subpopulations showed a degree of purification higher than 95%. 
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5.3.5 In vitro colony formation assay and quantification 
Freshly sorted cells of each subpopulation (500 cells) were plated onto irradiated 3T3L1 
feeder cells (5,000 cells) in 24-well Primaria plates (Becton Dickinson, Basel, Switzerland). 
The cells were cultured in DMEM/Ham F12 (Invitrogen, Zug, Switzerland) with 10% FCS, 
100 IU/ml penicillin, 100 μg/ml streptomycin (Invitrogen, Zug, Switzerland), 5 μg/ml bovine 
pancreatic insulin (Sigma, cell culture-tested solution, Buchs, Switzerland), 10 ng/ml mouse 
EGF (BD Biosciences, Basel, Switzerland), and 10 ng/ml cholera toxin (Sigma, Buchs, 
Switzerland). After 24 hours, the medium was renewed, and 4 days later, the colonies were 
fixed with acetone/methanol (1:1), washed, and rehydrated with PBS and 0.05% NaN3. In 
separate rescue experiments with selected mammary epithelial cells from parous mice, the 
incubation medium was supplemented with recombinant mouse Wnt4 (R&D Systems, 
Abingdon, UK) at 500 ng/ml. For quantification, colonies were immunofluorescently stained 
with Krt18 and Krt14 antibodies and with Hoechst 33342. The stained colonies were imaged 
with a MacroFluo Z16 microscope (Leica, Heerbrugg, Switzerland) at 2× magnification, and 
a Z1 microscope (Zeiss, Feldbach, Switzerland) at 5× magnification. The feeder cells served 
as negative controls for Krt18 and Krt14 staining. The number of colonies (that is, clusters of 
more than three cells [23]) per well was determined manually. Colonies defined as 
Krt18/Krt14 double-positive were double positive over a minimum of 20% of colony area. 
 
5.3.6 Mammary fat pad transplantation 
Freshly sorted basal stem/progenitor cells were resuspended in PBS with 50% Matrigel (BD 
Biosciences, Basel, Switzerland) and injected (30 µl) in limiting dilution numbers into the 
cleared fourth mammary glands of 3-week-old syngeneic female mice. Glands from recipient 
mice were harvested 8 to 9 weeks after transplantation, processed as whole mounts (see 
earlier), and scanned with an Epson Expression 1600 Pro scanner. The number of outgrowths 
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was counted, with an outgrowth defined as an epithelial structure with ducts starting from a 
central point and with lobules and/or terminal end buds (see Additional file 2) [27]. 
 
5.3.7 Microarray analyses 
Microarray analyses were performed on unsorted total mammary cell suspensions (see Figure 
2) and on FACS-sorted mammary cell subpopulations (see Figures 3 and 4, as well as Table 
1). For unsorted mammary cells, RNA was extracted by using the RNeasy Plus Mini Kit 
(Qiagen, Hilden, Germany). Genomic DNA was removed by using gDNA Eliminator Mini 
Spin Columns (Qiagen, Hilden, Germany). The RNA concentration was measured with a 
Nanodrop 1000 machine, and RNA quality determined with an Agilent 2100 bioanalyzer and 
RNA Nano Chips. Aliquots of 100 ng of isolated total RNA were amplified by using the 
Ambion WT Expression kit (Ambion, Zug, Switzerland). For FACS-sorted mammary 
epithelial cell subpopulations, total RNA was isolated by using the Arcturus PicoPure Frozen 
RNA Isolation Kit (Life Technologies, Zug, Switzerland). Genomic DNA was removed by 
using RNase-Free DNase (Qiagen, Hilden, Germany), the RNA concentration determined by 
using the RiboGreen Assay, and RNA quality assessed by using an Agilent 2100 bioanalyzer 
and RNA Pico Chips. Total RNA was used as the input for synthesis of amplified cDNA with 
the NuGen Ovation Pico WTA System (NuGen Inc., Leek, The Netherlands). 
 
Resulting double-stranded cDNA was fragmented and labeled by using the Affymetrix 
GeneChip WT Terminal Labeling kit (Affymetrix, High Wycombe, UK). Affymetrix Gene 
Chip Mouse gene 1.0 ST microarrays were hybridized according to the GeneChip Whole 
Transcript (WT) Sense Target Labeling Assay Manual (Affymetrix, High Wycombe, UK) 
with a hybridization time of 16 hours. The Affymetrix Fluidics protocol FS450_0007 was 
used for washing. Scanning was performed with Affymetrix GCC Scan Control Software v. 
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3.0.0.1214 on a GeneChip Scanner 3000 7G with autoloader. Arrays were normalized, and 
probeset-level expression values calculated with R/Bioconductor's (v2.14) “affy” package by 
using the rma() function. Differential gene expression between experimental and control 
samples was determined by using linear modeling as implemented in the R/Bioconductor 
package “limma.” For general analysis of gene  expression in total mammary cell suspensions 
and in FACS-sorted mammary cell subpopulations, we used the cut-off linear fold change 
>1.5, adjusted P value <0.05, and average linear expression between conditions greater than 
4. To determine the 10 most up- or downregulated genes in FACS-sorted mammary epithelial 
cell subpopulations, a cut-off of linear fold change >2.0, adjusted P value <0.001, and 
average linear expression between conditions ave>4 was used. For FACS-sorted mammary 
epithelial cell subpopulations both resulting lists of differential genes were imported into 
Ingenuity IPA (Ingenuity, content version 12710793) for pathway analysis. Gene-set 
enrichments in FACS-sorted mammary epithelial cell subpopulations were determined by 
using the JAVA application from the Broad Institute v2.0 [28,29] and gene sets v2.5 and 
v3.0, as well as custom gene sets (see Additional file 3). 
 
The microarray data from this publication have been submitted to the NCBI Gene Expression 
Omnibus [30] and are deposited as GSE40875 (mouse mammary cell subtypes), GSE40876 
(total mammary epithelial cells in mice), and GSE40877 (both total mammary epithelial cells 
and mammary cell subtypes in mice). 
 
5.3.8 Quantitative PCR 
RNA was isolated as described earlier and converted to cDNA by using the WT-Ovation 
Exon Module Version 1.0 (NuGen Inc., Leek, The Netherlands). Real-time PCR was 
performed on the unamplified cDNA corresponding to the specified number of cells or on 25 
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ng of amplified cDNA (by using the NuGen Ovation Pico WTA System (NuGen Inc., Leek, 
The Netherlands) for amplification). The TaqMan probe-based system was applied in 
combination with the TaqMan Universal PCR Master Mix (Applied Biosystems, Zug, 
Switzerland). The probe IDs are given later. Cycling was performed with 7500 Fast and Step 
OnePlus Real-Time PCR Systems (both from Applied Biosystems, Zug, Switzerland). 
 
5.3.9 Probe IDs for quantitative PCR 
These were the probes: Areg (Mm00437583_m1), Axin2 (Mm00443610_m1), B2M 
(Mm00437762_m1), Cdk8 (Mm01223097_m1), Cel (Mm00486975_m1), Csn1s1 
(Mm00514430_m1), Csn2 (Mm04207885_m1), Dsc2 (Mm00516355_m1), Dusp1 
(Mm00457274_g1), Esr1 (Mm00433149_m1), Fst (Mm00514982_m1), Gata3 
(Mm00484683_m1), Hprt (Mm00446968_m1), Id3 (Mm00492575_m1), Igfbp3 
(Mm_01187817_m1), Jag2 (Mm01325629_m1), Krt8 (Mm00835759_m1), Krt14 
(Mm00516876_m1), Krt15 (Mm00492972_m1), Krt19 (Mm00492980_m1), Lgr5 
(Mm00438890_m1), Ltf (Mm00434787_m1), Maml2 (Mm00620617_m1), Myc 
(Mm00487804_m1), Pgr (Mm00435628_m1), Sfrp1 (Mm00489161_m1), Ubc 
(Mm01201237_m1), Vcan (Mm01283063_m1), Wnt4 (Mm01194003_m1). 
 
5.3.10 Immunofluorescent staining 
For single-cell staining, freshly sorted cells were allowed to air-dry on poly-L-lysine-coated 
slides and stored at -20°C. The dried cells were blocked with PBS, 2.5% goat serum, and 
0.05% NaN3 for 60 minutes under UV light. The UV treatment was used to attenuate residual 
fluorescence from bound FACS antibodies. Primary antibody staining was performed 
overnight at 4°C by using Krt18 antibody (1:1,000) and Krt14 antibody (1:500) as luminal 
and basal cell markers, respectively. Secondary antibody staining was carried out for 60 
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minutes at room temperature by using anti-guinea pig Ig-Alexa488 (1:500) and anti-rabbit Ig-
Alexa546 (1:1,000). Hoechst 33342 (0.5 µg/ml; Invitrogen, Zug, Switzerland) staining was 
performed for 10 minutes at room temperature. The stained cells were mounted with ProLong 
Gold antifade reagent (Invitrogen, Zug, Switzerland) and imaged with a Z1 microscope 
(Zeiss, Feldbach, Switzerland) at 63× magnification. No primary antibody was added as a 
negative control. 
 
5.3.11 Immunohistochemistry 
The fourth mammary glands of parous or age-matched virgin control mice were collected 40 
days after weaning from mice in estrus. The glands were fixed in 4% PFA and embedded in 
paraffin. For immunostaining with ERα and PR, the sections were dewaxed and subjected to 
antigen retrieval by boiling in 10 mM citrate buffer for 10 minutes. Subsequently, the sections 
were cooled to room temperature, quenched for 10 minutes with PBS and 3% H2O2, and 
blocked for 30 to 60 minutes with PBS and 2.5% NGS. ERα and PR primary antibody 
staining was performed overnight at 4°C at a 1:1,000 (ERα) and a 1:200 (PR) dilution. 
Secondary antibody staining was carried out for 30 to 60 minutes at room temperature with 
biotinylated anti-rabbit IgG. Immunohistochemistry for versican, β-catenin, and p21 was 
performed on the Ventana DiscoveryXT instrument (Roche Diagnostics, Rotkreuz, 
Switzerland) by using the Research IHC Dap Map XT procedure. In brief, dewaxing was 
performed in the machine, and slides were pretreated with mildCC1 (versican and p21) or 
standardCC1 (β-catenin) (Roche Diagnostics, Rotkreuz, Switzerland). Primary antibodies 
were incubated at 37°C for 1 hour at the following dilutions: versican, 1:50; p21, 1:50; and β-
catenin, 1:500. As secondary antibody, Immpress, an anti-rabbit HRP conjugated polymer, 
was used. All slides were counterstained with Hematoxylin II (Roche Diagnostics, Rotkreuz, 
Switzerland) and Bluing Reagent (Roche Diagnostics, Rotkreuz, Switzerland). Images were 
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captured at 20-fold (ERα or PR) or 40-fold (versican, β-catenin, p21) magnification by using 
an Eclipse E600 microscope (Nikon, Egg, Switzerland). For quantification of ERα and PR 
positivity, at least 2,000 epithelial cells per mouse were counted. For quantification of nuclear 
β-catenin and p21, at least 500 epithelial cells per mouse were counted. The quantification of 
versican was performed with the MATLAB software by using color segmentation based on 
Mahalanobis distance to determine the pixels with a particular RGB-color distribution [31]. 
 
5.3.12 Determination of blood progesterone concentrations 
Blood was collected from the right atrium of mice in estrus in EDTA-covered tubes (Sarstedt, 
Numbrecht-Rommelsdorf, Germany), and plasma was extracted by centrifugation at 1,500 g 
for 15 minutes at 4°C. Progesterone concentrations were assessed with ELISA, as specified 
by the manufacturer’s guidelines (DRG, catalog no. EIA-1561, Marburg, Germany). 
 
5.3.13 Antibodies 
For flow cytometry, the following anti-mouse antibodies were used: PE-Cy7-CD45 (clone 
30-F11), FITC-CD24 (clone M1/69), PE-CD49f (clone GoH3) (all from BD Pharmingen, 
Basel, Switzerland), and APC-Sca1 (clone E13-161.7, from Biolegend, San Diego, USA).  
 
For immunofluorescent staining, the primary anti-mouse antibodies used were guinea pig 
keratin 18 (Krt18; Fitzgerald; catalog no. GP11, North Acton, USA) and rabbit keratin 14 
(Krt14; ThermoScientific, catalog no. RB-9020, Lausanne, Switzerland). The secondary 
antibodies used were anti-guinea pig Ig-Alexa488 and anti-rabbit Ig-Alexa546 (Molecular 
Probe, Invitrogen, Zug, Switzerland).  
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For immunohistochemistry staining, the primary antibodies included estrogen receptor alpha 
(ERα; Santa Cruz Biotechnology; catalog no. SC-542, Dallas, USA), progesterone receptor 
(PR; Clone SP2, ThermoScientific; catalog no. RM-9102, Lausanne, Switzerland), versican 
(Millipore/Chemicon; catalog no. ab1033, Billerica, USA), β-catenin (Cell Signaling; catalog 
no. 9587, Danvers, USA), and p21 (Abcam; catalog no. ab2961, Cambridge, UK). The 
secondary antibodies used were biotinylated anti-rabbit IgG (Vector Labs; catalog no. BA-
1000, Petersborough, UK) and anti-rabbit HRP conjugated polymer Immpress (Vector Labs; 
catalog no. MP-7401, Petersborough, UK). 
 
5.3.14 Statistics 
The limited dilution transplantation data were analyzed statistically as published previously 
[18]. The two-tailed unpaired Student t test was used to determine statistical significance of 
comparisons. 
 
5.3.15 Motif Activity Response Analysis (MARA) 
The MARA model [32] combines knowledge of gene-expression levels (measured by 
microarray) with transcription-factor binding sites to answer the question of which 
transcription factors are driving expression changes in mammary stem/progenitor cells in 
parous as compared with age-matched virgin control mice. Specifically, log-expression levels 
of all genes present on the microarray were modeled as linear combinations of transcription 
factor activities. The coefficients of these combinations were determined by the number of 
transcription-factor binding sites in the proximal promoter regions. For each transcription-
factor binding motif m and each sample (microarray) s, we estimated the activity Ams with the 
corresponding error. Furthermore, we quantified the significance of activity change of each 
binding motif in parous as compared with virgin control mice.  
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5.4 Results 
5.4.1 Early pregnancy decreases luminal Sca1+ cells, but does not change the 
proportions of the other mammary epithelial cell subpopulations 
To investigate the influence of early parity on the proportions of mammary epithelial cell 
subtypes, we first established FACS profiles of epithelial cell subpopulations in virgin FVB 
control mice [21,26]. Luminal CD24+High Sca1+ cells, luminal CD24+High Sca1- cells, basal 
CD24+Low Sca1- CD49fHigh cells, and basal CD24+Low Sca1- CD49fLow myoepithelial cells 
were isolated from these mice (Figure 1A). Use of the established cell markers keratin 18 
(Krt18) and keratin 14 (Krt14) confirmed the luminal and basal origin of the isolated cell 
subpopulations, and qPCR for CD49f and Sca1 affirmed the purity of the isolated cell 
subpopulations (see Additional file 4). Because basal CD49fHigh cells are considered to be 
enriched for basal mammary stem/progenitor cells in virgin mice [19,21], the term “basal 
CD49fHigh cells” is used synonymously with “basal stem/progenitor cells” throughout this 
article. To extend these analyses to parous mice, we confirmed that involution was complete 
28 and 40 days after weaning (see Additional file 5). To allow a margin of safety, 40 days 
after weaning was used for all subsequent cell-isolation experiments in a standardized 
parturition protocol with mating at 42 days (Figure 1B). The FACS profiles of epithelial cell 
subpopulations from parous mice and age-matched virgin control mice were similar (Figure 
1C, D; Additional file 1) with the exception of luminal Sca1+ cells, which decreased by about 
50% in parous mice (P = 0.02). Of note, luminal Sca1+ cells have been shown to be enriched 
for hormone receptor-positive cells [17]. This was verified by qPCR (see Additional file 6). 
These data demonstrate that the adopted experimental procedure permits the isolation of all 
epithelial cell subpopulations from parous mice, including basal stem/progenitor cells, at 
levels adequate for transcriptomic and functional analyses. 
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5.4.2 Parity upregulates differentiation genes in all cell subpopulations and decreases 
the Wnt/Notch signaling ratio in the basal stem/progenitor cell subpopulation 
Next we investigated the effects of early pregnancy on the gene-expression profiles of the 
isolated mammary epithelial cell subpopulations. To control for the effect of the cell-isolation 
procedure on gene expression, we performed first a transcriptome and cluster analysis in non-
FACS-sorted total mammary cell suspensions from age-matched virgin and parous mice 
(Figure 2A). The analysis showed that pregnancy induces an upregulation of many 
immunoglobulin and differentiation genes (for example, whey acidic protein Wap, and 
carboxyl ester lipase Cel) and a downregulation of growth factors (for example, amphiregulin 
Areg, betacellulin Btc, tumor-associated calcium signal transducer 2 Tacstd2), and 
extracellular matrix (ECM) elements (for example, laminin, gamma 2 Lamc2, desmocollin 2 
Dsc2). These data are consistent with the published pregnancy-induced gene signature 
determined in snap-frozen rodent mammary glands [9,10]. Thus, the gene signature was not 
lost during the isolation procedure, confirming the validity of our experimental system. 
Furthermore and most interestingly, a novel 3.4-fold downregulation of the Wnt signaling 
protein Wnt4 was observed in cells from parous mice (Figure 2). These microarray data were 
validated by qPCR for four genes, including Wnt4. Importantly, the expression of the luminal 
marker Krt8 was not altered on parity, demonstrating that the observed changes in gene 
expression were independent of unspecific alterations in total luminal cell numbers (Figure 
2B).  
 
Because the number of isolated basal stem/progenitor cells for gene-profiling analysis was 
limited compared with the other cell subpopulations (that is, myoepithelial, luminal Sca1-, 
and luminal Sca1+ cells), it was important to evaluate the influence of different cell numbers 
on transcriptome analysis. As shown in Additional Material, we found that it is valid to use 
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cell numbers in the range of 2,000 to 50,000 cells for comparison of transcriptomes from 
different mammary cell subpopulations (Additional file 6). Furthermore, qPCR analysis of 
nonamplified and amplified cDNA for known basal (Krt14) and luminal (Krt8; Krt19) cell 
marker genes confirmed that the amplification process of the microarray analysis was 
unbiased (Additional file 6). 
 
In the subsequent transcriptome analysis of FACS-sorted mammary epithelial cell 
subpopulations from age-matched virgin control and parous mice, all mammary epithelial cell 
subpopulations, except immune cell-depleted stromal cells, showed parity-induced changes in 
gene expression with by far the most prominent effects being scored for basal 
stem/progenitor cells (Figure 3A). Furthermore, although differentiation genes were 
upregulated in all epithelial cell subpopulations, the strongest prodifferentiation effects were 
seen in basal stem/progenitor cells from parous mice. For example, casein alpha 1 (Csn1s1), 
casein beta (Csn2), and lactotransferrin (Ltf) were upregulated 41-, 19-, and 14-fold, 
respectively (Figure 3B). Apart from these differentiation genes, the Notch co-activator 
Maml2 was found among the 10 most-upregulated genes (by fold change and/or by P value) 
in basal stem/progenitor cells from parous mice. In contrast, the 10 most-downregulated 
genes included the Wnt target and co-receptor Lgr5, the Wnt target and epithelial stem cell 
marker keratin 15 (Krt15) [33], and the Wnt targets versican (Vcan) and Igfbp3 [34] (Figure 
3B). Extension of the analysis to all data for signaling-pathway genes revealed further Wnt 
target genes, which were downregulated (for example, CD44 and follistatin (Fst) [35,36]), 
and the Wnt inhibitor Sfrp1, which was upregulated in basal stem/progenitor cells from 
parous mice. Moreover, in the same epithelial cell subpopulation of parous mice, the Notch 
ligand Jag2 and the Notch target genes Gata3, Id3, and Dusp1 were upregulated, whereas the 
Notch inhibitor Itch and the Maml2 RBP-J complex inhibitors Cdk8 and Pak1 [37] were 
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downregulated (Figure 3B). These gene-expression profiling data were validated with qPCR 
for several selected genes (Figure 3C). Furthermore, one of the classic Wnt target genes 
(versican) was examined on the protein level and found to be strongly downregulated in the 
basal compartment of mammary glands from parous mice (Figure 3D). Thus, the data 
demonstrate strong upregulation of differentiation genes, a downregulation of Wnt target 
genes, and an increase in Notch signaling in the basal stem/progenitor cell subpopulation of 
parous mice. 
 
Further verification of these conclusions came from Motif Activity Response Analysis 
(MARA) of transcription factor activities (see Methods) [38]. The canonical Wnt 
transcription factor LEF1/TCF7 was shown to have significantly decreased activity in basal 
stem/progenitor cells from parous mice (Figure 4A), which is consistent with the observed 
decrease in canonical Wnt signaling in the previous gene-expression profile analysis. 
 
Final confirmation of parity-induced downregulation of Wnt signaling in mammary glands 
was provided by immunohistochemical staining of mammary gland sections from age-
matched virgin control and parous mice for β-catenin. As illustrated in Figure 4B, nuclear β-
catenin was observed in basal but not in luminal mammary epithelial cells of virgin mice. In 
parous mice, the proportion of basal mammary epithelial cells positive for nuclear β-catenin 
was significantly decreased (Figure 4C). Because nuclear β-catenin is necessary for Wnt 
target gene expression, this finding represents an additional verification of parity-induced 
downregulation of Wnt signaling (Figure 3). 
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5.4.3 The parity-induced decrease in Wnt/Notch signaling ratio is specific for the basal 
stem/progenitor cell subpopulation 
To assess whether the observed decrease in canonical Wnt and increase in Notch signaling 
were specific for basal stem/progenitor cells, we next investigated the enrichment of 
Wnt/Notch signaling genes over all genes altered in the various FACS-sorted mammary 
epithelial cell subpopulations from parous as compared with virgin control mice. Such 
analysis showed that canonical Wnt signaling was significantly downregulated in basal 
stem/progenitor but not in luminal Sca1- or luminal Sca1+ cells from parous mice (Table 1; 
see Additional file 7). In myoepithelial cells, a trend toward a decrease in Wnt signaling was 
not significant when applying a very stringent cut-off (see Table 1 legend) and was probably 
due to contamination of the myoepithelial cell subpopulation with basal stem and/or 
progenitor cells. Similarly, Notch signaling was found to be significantly upregulated in basal 
stem/progenitor cells but in no other mammary epithelial cell subpopulation (Table 1). 
Whereas downregulation of Wnt and upregulation of Notch signaling were specific for basal 
stem/progenitor cells, similar enrichment analyses for genes involved in other signaling 
pathways revealed that the previously reported upregulation of the p53-p21 pathway [39] 
occurred in all epithelial cell subpopulations tested (Additional file 7). 
 
Further bioinformatics analysis of the data with different software [40] provided a second line 
of verification of the specific decrease in Wnt signaling in basal stem/progenitor cells after 
parity. Performing transcription-factor activity analyses based on target gene expression, we 
found TCF3, an inhibitor of the canonical Wnt signaling pathway [41], to be the transcription 
factor with the highest z-score (Z = 3.521) and the protooncogene MYC to have a very low z-
score (Z = -4.108) in basal stem/progenitor cells but not in other mammary epithelial cell 
subpopulations of parous mice (Figure 4D, z-score defined as (x-µ)/sd and used as a measure 
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for transcription factor activity based on the expression levels of target genes). These findings 
confirm the results obtained in the MARA analysis. Furthermore, inhibition of MYC leads to 
upregulation of Sfrp1, which in turn inhibits canonical Wnt signaling [42]. Upregulation of 
Sfrp1 was observed in the microarray analysis and validated with qPCR (Figure 3B, C), thus 
directly reflecting the expected effects of the bioinformatic predictions. 
 
Downregulation of canonical Wnt signaling and MYC activity would be expected to decrease 
the propensity for cancer, and indeed, in an analysis of biofunctions, a marked and consistent 
decrease in cancer-associated functions, was observed for basal stem/progenitor cells (Figure 
4E), but no other mammary epithelial cell subpopulation. This potential anticancer phenotype 
of basal stem/progenitor cells was underscored by gene-enrichment analyses on all available 
pathway gene sets (see Additional file 8), which showed a strong downregulation of 
proliferation- and tumorigenesis-associated gene sets. 
 
5.4.4 Parity decreases the in vitro clonogenic potential to the greatest extent in the basal 
stem/progenitor cell subpopulation 
Because decreased Wnt signaling and increased Notch signaling have been shown to decrease 
in vitro and in vivo proliferation of basal stem/progenitor cells [43,44], we next assessed the 
in vitro colony-formation capacities of mammary epithelial cell subpopulations from parous 
and age-matched virgin mice (Figure 5A). In virgin control mice, luminal Sca1- cells had the 
highest colony-formation capacity, with an average of 107 colonies per well (Figure 5B). 
This strong clonogenic potential suggests a pronounced progenitor identity of luminal Sca1- 
cells and is consistent with previous observations in younger virgin mice [16,17]. A high 
colony-formation capacity was also observed for the basal stem/progenitor cells of virgin 
mice (63 colonies per well) (Figure 5B), which is consistent with the notion that CD49fHigh 
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cells contain a high proportion of basal progenitor cells as well as putative mammary stem 
cells [45]. With the exception of luminal Sca1- cells, the colony-formation capacities of all 
epithelial cell subpopulations were lower in parous mice than in age-matched virgins (Figure 
5B). Thereby, by far the most pronounced difference was observed in basal stem/progenitor 
cells (Figure 5B). A substantial decrease in the colony-formation capacity was also seen for 
the myoepithelial cell subpopulation, which also contains basal progenitor cells. Of note, 
basal stem/progenitor cells from parous mice did not die but remained as quiescent single 
cells or divided only once during 5 days of culture (Figure 5C). 
 
The reduced progenitor potential of basal mammary epithelial cell subtypes and especially of 
basal stem/progenitor cells from parous mice was further confirmed by phenotypic analysis 
of colonies by colony size (cell number) and immunophenotyping of luminal and basal 
markers Krt18 and Krt14, respectively. The largest difference in colony size was observed for 
the basal stem/progenitor cell subpopulation, where parity induced a decrease in colonies of ≥ 
20 cells from 66% to 9% (Table 2A; Figure 5C). Considerably smaller parity-induced 
reductions in colony size were observed for the other epithelial cell subpopulations, although 
a substantial decrease was also seen for basal myoepithelial cells (Table 2A). With regard to 
Krt18/Krt14 double positivity, parity induced a reduction in Krt18/Krt14 double-positive 
colonies derived from basal stem/progenitor cells from 26% to 0 (Table 2A). In contrast, 
although Krt18/Krt14 double-positivity decreased by 27%, 57% of colonies derived from 
luminal Sca1- cells of parous mice maintained double positivity (Table 2A). No effects of 
parity on Krt18/Krt14 double positivity were observed for colonies derived from luminal 
Sca1+ or basal myoepithelial cells (Table 2A), whereby myoepithelial cells did not give rise 
to double-positive colonies even when originating from virgin control mice. Thus, consistent 
with the basal mammary stem/progenitor cell subpopulation-specific reduction in the 
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Wnt/Notch signaling ratio, parity decreased colony-formation capacity, in vitro proliferation 
potential (colony number and size), and Krt18/Krt14 double positivity most prominently in 
the basal stem/progenitor cell subpopulation. 
 
5.4.5 Parity decreases the in vivo reconstitution efficiency of the basal stem/progenitor 
cell subpopulation 
To test their proliferation potential in vivo, we transplanted basal stem/progenitor cells into 
deepithelialized mammary glands (“cleared fat pads”) [12]. It already was demonstrated that 
basal CD49fHigh cells have the highest mammary gland reconstitution ability of all mammary 
cell subpopulations in virgin mice [16,19]. Transplantation of FACS-isolated basal 
stem/progenitor cells into cleared fat pads demonstrated a significant decrease in the number 
of large outgrowths (≥10% and ≥25% of fat pad filled), indicating a decrease in the in vivo 
proliferation potential. Interestingly, when assessing also for rudimentary outgrowths (≥3% 
of fat pad filled), no significant difference in the number of outgrowths was observed 
between parous and virgin donors (Table 2B). Apart from the change in size, no qualitative 
differences were apparent between outgrowths from virgin and parous donors. In both cases, 
ductal as well as lobular structures were formed. Hence, early parity led to a reduction in in 
vivo mammary repopulating efficiency of FACS-isolated basal stem/progenitor cells, whereas 
their ability to differentiate into different mammary epithelial structures was maintained. 
 
5.4.6 Decrease in the proportion of Wnt4-secreting cells after early parity can explain 
decreased Wnt signaling and reduced proliferation capacity in basal mammary 
stem/progenitor cells 
Having observed most of the expected functional consequences of a decrease in the 
Wnt/Notch signaling ratio in basal stem/progenitor cells from parous mice, we finally 
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examined the possible cause of parity-induced reduction in canonical Wnt signaling and 
proliferation capacity in basal stem/progenitor cells. Because parity induced a greater than 
threefold decrease in Wnt ligand Wnt4 gene expression (Figure 2A, B), and Wnt4 is known to 
be secreted in response to progesterone by hormone-sensing luminal cells [46], thus inducing 
canonical Wnt signaling in mammary stem/progenitor cells [47], a parity-induced decrease in 
estrogen/progesterone-sensitive luminal cells could explain the overall decrease in Wnt 
signaling in mammary stem cells. This hypothesis is supported by the reduction in the 
proportion of luminal Sca1+ cells isolated from parous mice (Figure 1D) and by the 
demonstration that luminal Sca1+ cells are hormone receptor positive (Additional file 6) [17]. 
Furthermore, immunohistochemical analysis of mammary gland sections for estrogen 
receptor alpha (ERα) and its target progesterone receptor (PR) showed a twofold decrease in 
ERα- and a threefold decrease in PR-positive cells in parous compared with age-matched 
virgin control mice (Figure 6A, B). These results were additionally verified by qPCR in total 
mammary cell suspensions (Figure 6C). Notably, expression of the luminal marker Krt8 was 
similar in cell suspensions from parous and age-matched virgin control mice, supporting the 
conclusion of a specific decrease in hormone receptor-positive cells rather than a general cell 
loss after pregnancy. Furthermore, parity-induced reduction in progesterone-stimulated Wnt4 
expression was independent of blood progesterone, because average blood progesterone 
concentrations were similar in parous mice and age-matched virgin control mice in estrus 
(see Additional file 9). Finally, supplementation of the culture medium with recombinant 
Wnt4 stimulated in vitro proliferation capacity of basal myoepithelial and basal 
stem/progenitor cells from parous mice by +138% ± 22% and +140% ± 17%, respectively 
(Figure 7A). In contrast, no significant effects of recombinant Wnt4 on the colony-formation 
capacity of luminal Sca1- (+3.7% ± 3.0%) and luminal Sca1+ cells from parous mice (-5.1% ± 
2.9%) were observed. These data strongly suggest a causal relation between reduced number 
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of luminal progesterone receptor-positive/Wnt4-secreting cells and decreased Wnt/Notch 
signaling and proliferation potential of basal stem/progenitor cells after early pregnancy 
(Figure 7B). 
 
In conclusion, all collected data indicate that early parity induces a decrease in luminal 
hormone-sensing ERα- and PR-positive cells, which leads to decreased Wnt4 expression 
levels and to reduced Wnt signaling in basal stem/progenitor cells. Consistent with the 
decrease in the Wnt/Notch signaling ratio, differentiation is promoted and proliferation 
inhibited in basal stem/progenitor cells of parous mice. 
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5.5 Discussion 
This study demonstrates that a history of early pregnancy changes the gene-expression 
profiles and functional properties of mammary epithelial cell subpopulations in a cell 
subtype-specific fashion. Most important, the following parity-induced alterations were 
observed in mice: (a) an induction of differentiation and downregulation of the Wnt/Notch 
signaling ratio in basal stem/progenitor cells; (b) a decrease in the in vitro and in vivo 
proliferation potential of isolated basal stem/progenitor cells; (c) a selective downregulation 
of potentially tumorigenic biofunctions in the basal stem/progenitor cell subpopulation; (d) a 
reduction in estrogen- and progesterone-responsive and Wnt4-secreting luminal cells; and (e) 
a rescue of the proliferation defect in basal stem/progenitor cells in vitro by recombinant 
Wnt4. The finding of a decreased Wnt/Notch signaling ratio provides direct experimental 
evidence for the hypothesis that early pregnancy changes the “genomic signature” of 
mammary stem/progenitor cells [7], causing their differentiation and reducing their 
proliferation potential. Furthermore, the data indicate a novel causal relation between parity-
induced reduction in hormone-sensing and Wnt4-secreting luminal cells and altered 
biofunctions in basal stem/progenitor cells. 
 
The basal CD49fHigh cells, as isolated in this study, are a subfraction of basal epithelial cells 
[19,21]. Basal CD49fHigh cells have been demonstrated previously to be enriched in 
mammary repopulating units (MRUs) (known as mammary stem cells (MaSCs)) [16,19] and 
to correspond to the Lin- CD24+ CD29High epithelial cell subpopulation isolated by an 
alternative method [18,19,45]. However, the isolated basal CD49fHigh epithelial cell 
subpopulation represents a heterogeneous cell fraction containing, in addition to MaSCs, 
basal progenitor cells and possibly mature myoepithelial cells [45]. Progenitor cells can be 
characterized in vitro by their colony-formation capacity [22,23], whereas MaSCs have 
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traditionally been defined by their in vivo regenerative capacity [16-18]. The observed effects 
of parity on the in vitro and in vivo proliferation capacity of the CD49fHigh cell subpopulation 
(Table 2) suggests that both basal progenitor cells and basal MaSCs are the target of an early 
pregnancy within the mammary epithelium. Although the dramatic decrease in the in vitro 
proliferation capacity of the CD49fHigh cell subpopulation (Figure 5) indicates a predominant 
effect of an early pregnancy on basal progenitor cells, the additional reduction in large in vivo 
outgrowths (≥10% of fat pad filled) and the prevalence of rudimentary outgrowths (≥3% of 
fat pad filled) after parity (Table 2) suggest that isolated basal MaSCs are also affected by an 
early pregnancy. Because basal mammary stem and progenitor cells are closely related and 
likely to be interdependent in their proliferation potentials, our data do not permit a definite 
discrimination between basal stem and progenitor cells as primary targets of pregnancy. 
Therefore, we adhered to the combined term basal stem/progenitor cells throughout this 
study. 
 
We found the p53-p21 pathway to be enriched to a similar extent in all mammary epithelial 
cell subpopulations (Additional file 7) [39], and hence, although parity-caused induction of 
the p53-p21 pathway may explain the relatively modest decrease in in vitro colony-formation 
potential of the luminal Sca1+ cell subpopulation (Figure 5), it may contribute but cannot 
account for the almost complete proliferation block in basal stem/progenitor cells. The most 
prominent parity-induced alterations in gene expression in basal stem/progenitor cells were 
downregulation of the Wnt-signaling pathway, upregulation of the Notch-signaling pathway, 
and upregulation of differentiation genes. Decreased Wnt signaling in basal stem/progenitor 
cells from parous mice was verified on the protein level by measuring versican and nuclear β-
catenin expression (Figures 3D and 4B, C). Wnt signaling has been shown to promote long-
term expansion of cultured Lin- CD24+ CD29High cells and to provide a competitive 
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advantage in mammary gland reconstitution assays [43]. The latter is especially true for the 
expression of the classic Wnt target Lgr5 [48], which was found in our study to be 
downregulated in the basal stem/progenitor cell subpopulation after parity. Notably, Wnt 
signaling inhibition was demonstrated to have an antiproliferative effect in CD29High cells 
[43]. Furthermore, Notch signaling was observed to reduce in vitro and in vivo proliferation 
of CD29High cells while promoting their differentiation [44,49]. Because the differentiation 
processes of stem and progenitor cells in many organs and in several model systems are 
dependent on the Wnt/Notch signaling ratio [50], an overall reduction in Wnt/Notch signaling 
ratio would be expected to have a dramatic antiproliferation and prodifferentiation effect in 
mammary basal stem/progenitor cells. This is exactly what we observed in the CD49fHigh cell 
subpopulation of parous mice. Thereby, the overall conclusion of our study is strengthened 
by the fact that all assays used (that is, transcriptome analysis, bioinformatics transcription 
factor, and gene-enrichment analyses, in vitro colony-forming assay, in vivo transplantation 
assay, and immunohistochemistry) pointed into the same direction. Thus, analysis of specific 
mammary epithelial cell subpopulations allowed the discovery of a decrease in the 
Wnt/Notch signaling ratio, which so far is the only plausible explanation for the observed 
differentiation burst and dramatic proliferation block experienced by basal stem/progenitor 
cells of parous mice. 
 
As possible explanations for the parity-induced decrease in Wnt signaling, we found a 
marked increase in the activity of the Wnt repressor TCF3 in basal stem/progenitor cells and 
a more than threefold reduction in expression of the secreted Wnt ligand Wnt4 in total 
mammary cells from parous mice. The latter corresponded to a similar decrease in Wnt4-
secreting [46] and estrogen and progesterone receptor-positive luminal cells. Notably, a 
similar decrease in progesterone receptor α-positive cells after parity has also been observed 
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in human breast epithelium [51]. Hence, mechanistically, early parity decreases the hormone 
responsiveness of the mammary gland in mice by decreasing the number of 
estrogen/progesterone receptor-positive luminal cells. This reduces the paracrine signaling 
cascade mediated by Wnt4, inducing TCF3-dependent repression [52] and/or primary 
downregulation [47] of canonical Wnt signaling and secondary (reactive) upregulation of 
Notch signaling in basal stem/progenitor cells.  
As a final consequence, proliferation is repressed and basal stem/progenitor cells 
differentiate. This mechanistic model is supported by the ability of recombinant Wnt4 to 
rescue the proliferation defect of basal stem/progenitor cells from parous mice in vitro 
(Figure 7). 
 
Our findings in specific mammary epithelial cell subpopulations are in part consistent with 
and in part contradictory to studies in entire breasts/mammary glands, total mammary cells, 
or total mammary epithelial cells. With respect to the transcriptome analysis, our studies in 
total mammary cells agree with previous reports in the entire mammary glands [9,10]. 
However, in intact mammary glands or total mammary cells, the additional presence of 
stromal and dominant epithelial cell subtypes might mask the detection of key signaling-
pathway changes. Indeed, our study demonstrates that isolation of specific mammary 
epithelial cell subpopulations is a prerequisite for the detection of a decrease in Wnt/Notch 
signaling ratio in basal stem/progenitor cells. A similar masking effect by stromal and 
dominant epithelial cell subtypes (for example, strong clonogenic luminal Sca1- cells) might 
also explain why a previous study with a similar early-pregnancy protocol did not observe a 
parity-induced reduction in in vitro proliferation of total mixed mammary cells [20]. 
Controversial results have also been reported with respect to the effect of parity on the in vivo 
mammary-repopulating capacity. Hence, although Britt et al. [21] found no effects of late 
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pregnancy (9 weeks) on mammary-repopulating units (MRUs) in total mammary epithelial 
cells, Siwko et al. [20] (early-pregnancy protocol) observed a parity-induced reduction in the 
mammary-repopulating capacity of total mixed mammary cells. With a similar early-
pregnancy protocol and the same cut-off for mammary gland outgrowth (≥10% of fat pad 
filled), our findings in isolated mammary basal stem/progenitor cells appear consistent with 
the observations of Siwko et al. However, given that our studies were performed with 
isolated mammary basal stem/progenitor cell subpopulations, our findings are not directly 
comparable with and neither confirm nor contradict previous studies using total mammary 
(epithelial) cells [20,21]. Furthermore, the fact that the number of smaller outgrowths (≥3% 
of fat pad filled) was unchanged after parity suggests that MRUs survive after pregnancy 
despite their reduced reconstitution efficiency. This conclusion is in line with the recent 
demonstration that Wnt-responsive mammary epithelial stem cells persist after parity in 
Axin2 reporter mice [15]. 
 
It is intriguing to speculate that marked growth inhibitory effects and the downregulation of 
canonical Wnt signaling in basal stem/progenitor cells account, at least in part, for the cancer-
protective effect of early pregnancy. Increases in canonical Wnt signaling have been linked 
repeatedly to oncogenesis [53,54]. Moreover, downregulation of the Wnt inhibitory protein 
Sfrp1 and overexpression of the Wnt target versican have been associated with 
carcinogenesis [55,56]. In the transcriptome analysis reported here, Sfrp1 was upregulated 
and versican downregulated, thus supporting a parity-induced anticarcinogenic effect. 
Moreover, Li et al. [57] showed that transgenes encoding components of the Wnt signaling 
pathway preferentially induce mammary cancers from progenitor cells. Hence, the 
contribution of decreased canonical Wnt signaling in basal stem/progenitor cells to the 
cancer-protective effect of early pregnancy may be in conjunction with other tumor-
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suppressing mechanisms, such as parity-induced induction of p53 [58,59]. Thereby, the 
increase in the TCF3 repressor activity in basal stem/progenitor cells is expected to elevate 
the threshold further for the activation of tumorigenic Wnt signaling [52]. In addition to 
decreased Wnt signaling in basal stem/progenitor cells, decreased ERα- and PR-positive cells 
could also be a mechanism for the breast cancer-protective effect of an early pregnancy. This 
is especially relevant, given the specific protective effect of pregnancy against ER/PR-
positive tumors [60]. 
 
Furthermore, mammary epithelial cell differentiation per se has been suggested to exert a 
breast cancer-protective effect. This has been challenged, however, by the observation that 
differentiation-causing agents such as placental lactogen and perphenazine failed to protect 
against carcinogenesis in rodents [3,61]. Also, the hypothesis of a potential breast cancer-
protective effect of mammary stromal cells [62] is not supported by our study, because 
stromal cells exhibited by far the fewest parity-induced gene-expression changes. However, 
our stromal cell subpopulation was not homogenous and devoid of immune cells, which may 
have masked some parity-induced alterations. In any case, the parity-induced downregulation 
of the Wnt/Notch signaling ratio in basal stem/progenitor cells represents a possible 
important mechanism for the breast cancer-protective effect of early pregnancy. 
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5.6 Conclusions 
This study identified downregulation of the Wnt/Notch signaling ratio in basal 
stem/progenitor cells as the dominant early parity-induced alteration of gene expression in 
mice. This change in gene expression is specific for basal mammary stem/progenitor cells, is 
associated with proliferation defects in vitro and in vivo, and is probably caused by an early 
parity-induced decrease in hormone-sensitive and Wnt4-secreting luminal cells. Importantly, 
because a similar reduction in progesterone receptor α-positive luminal cells has been 
reported in women [51], parity-induced alterations in Wnt/Notch signaling pathways may 
also occur in human basal stem/progenitor cells. Testing whether Wnt inhibitors mimic early 
parity-induced breast cancer protection warrants further investigation. 
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5.7 Abbreviations 
ER, estrogen receptor; FDR, false discovery rate; FWER, family-wise error rate; GSEA, 
gene-set enrichment analysis; MARA, motif activity response analysis; MaSC, mammary 
stem cell; MRU, mammary repopulating unit; NES, normalized enrichment score; PR, 
progesterone receptor; RBC, red blood cell; WBC, white blood cell. 
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5.9 Figure legends 
Figure 1. The CD24/Sca1 and CD49fHigh/CD24 flow-cytometry profiles of parous and 
age-matched virgin mice are similar. (A) Schematic illustration of the cell-isolation 
strategy and representative flow-cytometry pseudocolor plots of mammary cells from age-
matched virgin control mice. After depletion of CD45+ white blood cells, luminal and basal 
mammary epithelial cells were separated on the basis of CD24 and Sca1 expression. Further 
separation of basal cells into myoepithelial and basal stem/progenitor cell subpopulations was 
based on the expression of CD24 and CD49f. The isolated mammary epithelial cell 
subpopulations included luminal Sca1+ (CD24+HighSca1+) cells, luminal Sca1- 
(CD24+HighSca1-) cells, basal CD49fHigh (CD24+LowSca1-CD49fHigh) or basal stem/progenitor 
cells, and basal myoepithelial (CD24+LowSca1-CD49fLow) cells. (B) Outline of the mouse 
mating, parturition, weaning, and involution protocol. (C) Representative flow-cytometry 
pseudocolor plots of mammary cells from parous mice. The gates applied were the same as 
those for age-matched virgin controls. (D) Bar graph showing the distribution of mammary 
epithelial cell subpopulations comparing cells from parous with age-matched virgin control 
mice. Data represent the mean ± SEM of seven cell-isolation experiments with a minimum of 
10 mice per experiment. The proportion of luminal Sca1+ cells was reduced by approximately 
50% in parous mice (P = 0.02 with a two-tailed unpaired Student t test). 
 
Figure 2. Parity-induced gene signature in total mammary cell suspensions. (A) Heat-
map and cluster analysis of differential gene expression in total isolated mammary cells from 
age-matched virgin control and parous mice. Gene expression is presented as normalized Z-
scores, defined as Z = (x-µ)/sd to allow visualization. A cut-off of P < 0.05 was applied. If 
multiple probe sets existed for the same gene, the probe set with the largest change in 
expression was selected. Four independent experiments were performed with 10 mice (five 
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virgins; five parous) per experiment. (B) qPCR validation of pregnancy-induced gene-
expression changes in total mammary cell suspensions. Fold changes are shown in relation to 
expression in cell suspensions from age-matched virgin control mice. Ct values were 
normalized to the reference gene Hprt. As control for luminal epithelial cell number, qPCR 
for Krt8 was performed. Data represent the mean ± SEM of four independent experiments 
with 10 mice (five virgins; five parous) per experiment. 
 
Figure 3. Parity leads to differentiation and decreases the Wnt/Notch signaling ratio in 
basal stem/progenitor cells. (A) Bar graph depicting the number of gene-expression changes 
in FACS-sorted mammary stromal and epithelial cell subpopulations from parous mice 
compared with age-matched virgin control mice by using a cut-off of fold change >1.5 and an 
adjusted P value <0.05. By far the most gene-expression changes were observed in basal 
stem/progenitor cells. Three independent experiments were performed with 10 mice (five 
virgins; five parous) per experiment. (B) Schematic illustration of prominent gene-expression 
changes in FACS-sorted basal stem/progenitor cells from parous as compared with age-
matched virgin control mice. Fold changes are shown in parentheses with upregulated genes 
denoted as positive (+), and downregulated genes, as negative (-). Differentiation genes were 
upregulated (blue), Wnt target genes were downregulated (green), Wnt inhibitor Sfrp1 was 
upregulated (green) and overall Notch signaling (orange) was increased in basal 
stem/progenitor cells from parous mice. (C) qPCR validation of the changes in gene 
expression in basal stem/progenitor cells of parous mice. All classic Wnt target genes were 
downregulated, including Lgr5, Axin2, and versican (Vcan), whereas the more ubiquitously 
regulated target Myc was unchanged. In all cases, fold changes are shown relative to cells 
from age-matched virgin control mice. Ct values were normalized to the reference genes Hprt 
and Ubc [63]. Data represent the mean ± SEM of three independent experiments with 10 
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mice (five virgins; five parous) per experiment. (D) Representative images and quantification 
of immunostaining for the Wnt target gene versican in mammary gland sections from age-
matched virgin and parous mice in estrus. Scale bar, 50 µm. Quantitative data represent the 
mean ± SEM from 60 randomly selected images from three virgin and three parous mice. 
 
Figure 4. Effects of parity on Wnt transcription-factor activities and nuclear β-catenin 
in basal mammary epithelial cells. (A) Wnt transcription factor LEF1/TCF7 motif activity 
in basal stem/progenitor cells from parous as compared with virgin control mice, as predicted 
by MARA [32]. The binding motif of the LEF1/TCF7 transcription factor is shown in color. 
(B) Representative images of immunostaining for β-catenin in mammary gland sections from 
age-matched virgin and parous mice in estrus. Arrow, basal mammary epithelial cells with 
nuclear β-catenin. Arrowhead, basal mammary epithelial cells lacking nuclear β-catenin. 
Scale bar, 10 µm. (C) Bar graph representing the quantification of nuclear β-catenin in 
mammary gland sections of virgin and parous mice. Data represent the mean ± SD (virgin 
mice: n = 3; parous mice: n = 3). P = 0.004 with the two-tailed unpaired Student t test. (D) 
Transcription-factor activities in basal stem/progenitor cells, predicted on the basis of target 
gene expression by Ingenuity IPA [40]. Activity is reported as Z scores (positive Z score, 
upregulation; negative Z score, downregulation) by using a cut-off of linear fold change >1.5 
and P value <0.05. (E) BioFunctions most strongly downregulated (blue) or upregulated 
(orange) in basal stem/progenitor cells, as calculated by Ingenuity IPA [40]. The color of the 
fields represents the Z score; the size of the fields represents the number of genes. A stringent 
cut-off of linear fold change >2 and P value <0.01 was used to minimize the number of false 
positives. 
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Figure 5. Parity reduces the progenitor potential of mammary epithelial cell 
subpopulations. (A) Representative images of individual wells with colonies formed by the 
specified cell subpopulations from age-matched virgin and parous mice. Scale bar, 4 mm. (B) 
Bar graph comparing the colony-forming capacities of myoepithelial cells, basal 
stem/progenitor cells, luminal Sca1-, and luminal Sca1+ cells of age-matched virgin and 
parous mice. Data are from three independent experiments and represent the mean ± SEM of 
colonies per well; 18 wells were assessed per cell type. *P < 0.015, NS: not significant (P = 
0.08), by using two-tailed unpaired Student t test. (C) Representative images for the 
immunophenotyping of 5-day-old colonies grown from myoepithelial cells, basal 
stem/progenitor cells, luminal Sca1-, and luminal Sca1+ cells. The colonies were stained for 
luminal Krt18 (green) and basal Krt14 (red) expression. Hoechst 33342 (blue) was used to 
distinguish nuclei and to label feeder cells (negative control). Scale bar, 200 µm. 
 
Figure 6. Early pregnancy decreases the proportion of progesterone receptor (PR) and 
estrogen receptor α (ERα)-positive cells. (A) Representative images of immunostaining for 
PR and ERα in mammary gland sections from age-matched virgin and parous mice in estrus. 
Scale bar, 50 µm. (B) Bar graph comparing the relative frequency of estrogen- and 
progesterone receptor-positive cells between mammary glands of virgin and parous mice. 
Data represent the mean ± SD (virgin mice, n = 6; parous mice, n = 5). For PR, P = 3.70E-07; 
for ERα, P = 0.003, by using two-tailed unpaired Student t test. (C) qPCR for progesterone 
receptor (Pgr), estrogen receptor alpha (Esr1), and the luminal marker keratin 8 (Krt8) genes 
in total mammary cell suspensions. Data are expressed as the mean ± SEM from four groups 
of a minimum of five parous and five age-matched virgin control mice. 
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Figure 7. Effect of Wnt4 on the proliferation capacity of basal stem/progenitor cells 
after early pregnancy in mice. (A) Recombinant Wnt4 rescues the parity-induced in vitro 
proliferation defect in basal mammary epithelial cells. Selected mammary epithelial cells 
from parous mice were cultured in the absence or presence of recombinant Wnt4. Three 
independent experiments were performed. Data represent the mean ± SEM of colonies per 
well, with six to nine wells assessed per cell type. *P ≤ 0.02 (two-tailed unpaired Student t 
test). (B) Mechanistic model illustrating the parity-induced decrease in hormone-sensing and 
Wnt4-secreting luminal cells on the Wnt/Notch signaling pathways and the 
proliferation/differentiation potential in basal stem/progenitor cells. 
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Figure 5 Meier-Abt et al.
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Figure 7 Meier-Abt et al.
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5.10 Tables 
Table 1: Wnt signaling is decreased and Notch signaling is upregulated in basal 
stem/progenitor cells 
 Wnt signaling Notch signaling 
NES P-value FDR FWER NES P-value FDR FWER 
Myoepithelial -1.47 0.03 0.06 0.04 1.08 0.35 0.34 0.74 
Basal stem/progenitor -1.70 <0.01 <0.01 <0.01 1.64 <0.01 0.02 0.01 
Luminal Sca1- -1.08 0.33 0.64 0.37 1.08 0.32 0.62 0.45 
Luminal Sca1+ -0.68 0.99 0.99 0.74 0.83 0.77 1.00 0.93 
 
Gene set enrichment analysis (GSEA) for Wnt and Notch signaling as defined by the 
expression of Wnt or Notch target genes (see Methods) showed a decrease in the Wnt/Notch 
signaling ratio (strongly negative/positive normalized enrichment scores (NES)), which was 
specific for the basal stem/progenitor cells. Significance was determined by a cut-off of a 
nominal P-value <0.01, a false discovery rate (FDR) <0.05 and a family-wise error rate 
(FWER) <0.05 as suggested by the GSEA homepage [28]. The gene set for Wnt signaling 
consisted of the reported Wnt targets in mammalian systems (derived from the Stanford Wnt 
homepage) and is depicted in Additional file 3. The gene set for Notch signaling was derived 
from the Broad Institute v3.0 and is termed Nguyen Notch1 targets. The number of 
permutations was set to 1000 and the permutation type was set to ‘gene set’, since there were 
less than 7 samples per phenotype [28]. Otherwise, the default settings were used. 
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Table 2: Functional characterization of isolated epithelial cell subpopulations 
A Fraction of large colonies  Fraction of double positive 
colonies 
 Virgins Parous Virgins Parous 
Myoepitheliala 32.7±7.4%a 9.6±2.3%a 0% 0% 
Basal stem/progenitora 66.2±7.2%a 9.3±4.5%a 26.1±2.7% 0% 
Luminal Sca1-b 36.3±5.6%b 31.3±2.6%b 84.0±3.4% 57.1±2.9% 
Luminal Sca1+a 73.3±1.8%a 71.8±4.1%a 64.1±3.6% 59.8±2.7% 
acolony size ≥ 20 cells; bcolony size ≥ 100 cells 
B, Number of basal 
stem/progenitor cells injected 
per cleared fat pad 
Number of positive outgrowthsc,d,e
Age-matched virgin control 
donors 
Parous donors 
1000 c8/9     d8/9     e8/9 c3/9     d3/9     e4/9 
500 c8/11   d8/11   e8/11 c2/11   d2/11   e6/11 
250 c2/6     d2/6     e2/6 c0/6     d1/6     e1/6 
100 c0/6     d1/6     e1/6 c0/6     d0/6     e2/6 
50 c0/7     d0/7     e0/7 c1/7     d1/7     e1/7 
Repopulating frequency (95% 
confidence interval) 
c1/507 (1/827 – 1/311) 
d1/472 (1/767 – 1/291) 
e1/472 (1/767 – 1/291) 
c1/2468 (1/5522 – 1/1104) 
d1/2095 (1/4441 – 1/988) 
e1/907 (1/1582 – 1/520) 
P value cP = 0.0004; dP = 0.0004; eP = 0.076 
cpositive outgrowth defined as ≥ 25% of fat pad filled; dpositive outgrowth defined as ≥ 10% 
of fat pad filled; epositive outgrowth defined as ≥ 3% of fat pad filled 
 
A, Size and phenotype (Krt18/Krt14 double positivity) of colonies. At least 50 randomly 
selected colonies were examined for each group except for colonies derived from basal 
stem/progenitor cells of parous mice where all available colonies were used. Data represent 
the means ± SEM of three independent experiments with a minimum of 10 mice (5 virgins; 5 
parous) per experiment. 
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B, Limiting dilution analysis of the repopulating capacity. The basal stem/progenitor cell 
subpopulations from parous (n=23) and age-matched virgin control (n=21) mice were 
injected into the cleared fat pads of 3-week-old syngeneic female recipient mice in limiting 
dilution numbers. Epithelial outgrowths were scored 8-9 weeks after injection. Number of 
positive outgrowths of specified sizes is indicated per number of mammary fat pads injected 
(i.e., X outgrowths per Y injections = X/Y). When analyzed statistically as previously 
described [18], a significant decrease in the number of large outgrowths was observed for 
parous donors. 
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5.11 Additional file legends 
Additional file 1. Flow-cytometric separation of mammary epithelial cells from virgin 
control and parous mice. Representative flow-cytometry pseudocolor plots depicting the 
first steps in the gating strategy used to eliminate doublets, cell clumps, dead cells (DAPI 
bright) and white blood cells (CD45+) during the procedure for isolating mammary epithelial 
cell subpopulations from virgin control (A) and parous (B) mice. Subsequent isolation steps 
are shown in Figure 1. (C) Bar graph showing the proportion of mammary epithelial cells 
relative to the total white blood cell depleted (CD45-) mammary cells. The apparent modest 
decrease in total epithelial cells from parous mice was not significant (P = 0.05 by using two-
tailed unpaired Student t test). 
 
Additional file 2. Basal stem/progenitor cells from parous mice show reduced in vivo 
proliferation potential. Examples of an outgrowth (left) and of no outgrowth (right) from 
basal stem/progenitor cells of age-matched virgin control mice and of parous mice, 
respectively. 
 
Additional file 3. Custom gene set of Wnt target genes. The gene set is composed of the 
Wnt targets that have been reported to be upregulated on canonical Wnt signaling in 
mammalian systems [64]. 
 
Additional file 4. Verification of luminal/basal origin and purity of isolated mammary 
epithelial cell subpopulations. (A) Immunofluorescent staining of isolated mammary 
epithelial cells with the luminal marker keratin 18 (Krt18) and the basal marker keratin 14 
(Krt14). Basal myoepithelial cells were negative for Krt18 and positive for Krt14 in >95% of 
total cells. Conversely, luminal Sca1- and luminal Sca1+ cells were positive for Krt18 and 
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negative for Krt14 in >95% of total cells. These data confirm the basal and luminal origin of 
the isolated cell subpopulations. Basal stem/progenitor cells were positive for Krt14 and 
Krt18 in >95% and about 20% of total cells, respectively. Data are representative of three 
independent experiments. Scale bar, 50 µm. (B/C) qPCR for CD49f and Sca1 in FACS-sorted 
mammary epithelial cell subpopulations. Fold changes are shown relative to myoepithelial 
cells. Data are expressed as the mean ± SEM of three independent experiments. 
 
Additional file 5. Control for complete involution. Representative images of whole mounts 
of mammary glands from virgins and parous mice 28 and 40 days after weaning. Mammary 
glands were completely involuted at 28 days and certainly at 40 days after weaning. 
 
Additional file 6. Influence of cell number on transcriptome analysis and validation of 
the amplification method. (A) Pairwise correlation plot of transcriptome data derived from 
2,000 and 50,000 myoepithelial and luminal Sca1- cells, and from 2,000 basal CD49fHigh 
stem/progenitor cells isolated from 11-week-old virgin mice (n = 6). Individual arrays were 
pairwise correlated by using the unfiltered data as input. Pearson correlation coefficients were 
calculated and mapped onto a gray scale from black (low values) to white (high values). 
Higher cell numbers resulted in higher reproducibility, as assessed by high Pearson 
correlation coefficients. However, although lower cell numbers resulted in lower Pearson 
correlation coefficients, all arrays of one cell subpopulation were clearly discernible from 
other subpopulations, irrespective of the cell number used. Thus, in the range of 2,000 to 
50,000 cells, cell-subpopulation identity was more determining for cluster analyses than cell 
number. (B) qPCR on amplified cDNA of mammary epithelial cell subpopulations. Data 
were normalized to the reference gene B2M and are shown relative to 50,000 cells of 
myoepithelial cells. The basal marker keratin 14 (Krt14) was expressed by myoepithelial 
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cells and basal CD49fHigh stem/progenitor cells, but not by luminal Sca1- and luminal Sca1+ 
cells. Conversely, the luminal markers keratin 8 (Krt8) and keratin 19 (Krt19) were expressed 
by luminal Sca1- and luminal Sca1+ cells, but not by myoepithelial and not by basal 
CD49fHigh stem/progenitor cells. As expected, the estrogen receptor alpha (Esr1) was 
expressed by luminal Sca1+ cells only. Data represent the means of duplicates. (C) qPCR on 
unamplified cDNA. Data were processed and analyzed as in (B). Changes in expression 
levels of the luminal and basal markers Krt19 and Krt14, respectively, were similar to those 
of amplified cDNA, indicating that the amplification process was unbiased. 
 
Additional file 7. The decrease in Wnt signaling is specific for basal stem/progenitor 
cells, whereas the p53-p21 pathway is upregulated to the same degree in all mammary 
epithelial cell subpopulations from parous mice. (A) Enrichment plots of Wnt target gene-
set enrichment analysis [28,29] for isolated mammary epithelial cell subpopulations. The 
enrichment score is plotted against the ranked gene list, calculated by subtracting the gene 
expression levels of cells from age-matched virgins and parous mice. The gene set contained 
all canonical Wnt target genes reported in mammalian systems (Additional file 3). Thus, 
positive enrichment scores indicate an upregulation, and negative enrichment scores, a 
downregulation of Wnt signaling in cells of parous mice. Statistical analysis indicated 
specific downregulation of Wnt signaling in basal stem/progenitor cells from parous mice 
(Table 1). The apparent downregulation of Wnt signaling in myoepithelial cells, which are 
contaminated with basal stem/progenitor cells, was not significant. (B) Bar plot of gene-set 
enrichment analysis (GSEA)-calculated and normalized enrichment scores for the p53-p21 
pathway previously identified by Sivaraman et al. [39]. The p53-p21 gene set was rendered 
by GSEA as significantly upregulated in all isolated mammary epithelial cell subpopulations 
from parous mice when testing for all signaling-pathway gene sets contained in v2.5 and 
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v3.0. The nominal P value, the false discovery rate (FDR), and the family-wise error rate 
(FWER) for this pathway were <0.01 for all mammary epithelial cell subpopulations; 1,000 
permutations were performed with the permutation type “gene set.” (C) Representative 
images of immunostaining for p21 and bar graph comparing the relative frequency of p21-
positive epithelial cells in mammary gland sections from age-matched virgin and parous mice 
in estrus. Data represent the mean ± SD (virgin mice: n = 3; parous mice: n = 3). P = 0.0007, 
by using two-tailed unpaired Student t test. Scale bar, 25 µm. 
 
Additional file 8. Twenty most significantly downregulated pathways in basal 
stem/progenitor cells after parity. The list was calculated by using v3.0 of GSEA [28]. The 
1,000 permutations were performed by using the permutation type “gene set.” In all other 
cases, the default settings were used. 
 
Additional file 9. Blood progesterone concentrations in parous and age-matched virgin 
control mice in estrus do not change significantly. Plasma progesterone levels were 
measured with ELISA. 
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Additional file 3 
 
Custom gene set of Wnt target genes 
 
 
MYC 
CCND1 
TCF7 
LEF1 
PPARD 
JUN 
FOSL1 
PLAUR 
MMP7 
AXIN2 
NRCAM 
TCF4 
GAST 
CD44 
CLDN1 
BIRC5 
VEGFA 
FGF18 
ATOH1 
MET 
EDN1 
MYCBP 
L1CAM 
ID2 
JAG1 
TIAM1 
NOS2 
DKK1 
FGF9 
LBH 
FGF20 
LGR5 
SOX17 
RUNX2 
GREM1  
SALL4 
CYR61 
SOX2 
PTTG 
DLL1 
FOXN1 
MMP26 
NANOG 
POU5F1 
SNAI1/2 
FN1 
FZD7 
FST 
 
 
 
 
 
WNT3A 
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MMP9 
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IGF1 
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CDX4 
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EGFR 
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OVOL1 
CTLA4 
FGF4 
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TNFRSF19 
IGFBP3 
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Additional file 8             Meier-Abt et al.
Twenty most significantly downregulated pathways in basal stem/progenitor cells 
after parity 
 
Gene set name NES NOM p-
value 
FDR q-
value 
FWER 
p-value 
KOBAYASHI_EGFR_SIGNALING_24HR_DN -3.10156 <0.01 <0.01 <0.01 
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP -3.09002 <0.01 <0.01 <0.01 
ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER -3.03387 <0.01 <0.01 <0.01 
SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6 -2.91205 <0.01 <0.01 <0.01 
HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_UP -2.87939 <0.01 <0.01 <0.01 
GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_UP -2.81022 <0.01 <0.01 <0.01 
FURUKAWA_DUSP6_TARGETS_PCI35_DN -2.7968 <0.01 <0.01 <0.01 
ODONNELL_TFRC_TARGETS_DN -2.77325 <0.01 <0.01 <0.01 
WINNEPENNINCKX_MELANOMA_METASTASIS_UP -2.7715 <0.01 <0.01 <0.01 
CROONQUIST_IL6_DEPRIVATION_DN -2.76799 <0.01 <0.01 <0.01 
BENPORATH_PROLIFERATION -2.71965 <0.01 <0.01 <0.01 
WHITEFORD_PEDIATRIC_CANCER_MARKERS -2.71767 <0.01 <0.01 <0.01 
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP -2.71177 <0.01 <0.01 <0.01 
LEE_EARLY_T_LYMPHOCYTE_UP -2.70924 <0.01 <0.01 <0.01 
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN -2.69762 <0.01 <0.01 <0.01 
KANG_DOXORUBICIN_RESISTANCE_UP -2.6926 <0.01 <0.01 <0.01 
FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_UP -2.6593 <0.01 <0.01 <0.01 
BERENJENO_TRANSFORMED_BY_RHOA_UP -2.64615 <0.01 <0.01 <0.01 
PUJANA_BRCA2_PCC_NETWORK -2.63882 <0.01 <0.01 <0.01 
WILCOX_PRESPONSE_TO_PROGESTERONE_UP -2.63688 <0.01 <0.01 <0.01 
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Additional file 9             Meier-Abt et al.
 
 
Plasma progesterone levels in mice 
 
 Average plasma progesterone 
concentration (ng/mL) ± s.d. 
Age-matched virgin control mice in estrus (n=5) 4.6 ± 1.8 
Parous mice in estrus (n=6) 3.2 ± 0.9 
P value 0.14 
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6. GENERAL DISCUSSION 
This study shows that early pregnancy does indeed induce cell autonomous processes that 
potentially can explain the observed breast cancer protective effect of early parity in rodents 
and in humans. More specifically, isolation of similar mammary epithelial cell 
subpopulations in parous and age-matched virgin control mice revealed that early pregnancy 
changes the “cell fates” of specific mammary epithelial cell subtypes by inducing cell 
subtype-specific alterations in gene expression profiles, proliferation capacities, and 
differentiation potentials. Most importantly, early pregnancy induced a decrease in the 
Wnt/Notch signaling ratio in the basal mammary stem/progenitor cell subpopulation. This 
alteration of cell fate determining signaling pathways was accompanied by a more 
differentiated phenotype and by a decrease in the in vitro proliferation and differentiation 
potentials. Whereas in vivo the proliferation potential of basal stem/progenitor cells was also 
reduced after early pregnancy, the differentiation potential remained unchanged. 
Furthermore, early pregnancy reduced the response of the mammary gland to progesterone 
signaling by decreasing the proportion of estrogen and progesterone receptor positive luminal 
cells, resulting in reduced expression of the progesterone target Wnt4 despite constant 
progesterone plasma levels. Thereby, decreased Wnt4 expression may well explain parity-
induced reduction in Wnt signaling and associated proliferation failure in basal 
stem/progenitor cells, especially because recombinant Wnt4 rescued the parity-induced 
proliferation defects of this cell subpopulation. Hence, the findings suggest a direct link 
between reduced numbers of hormone receptor positive luminal cells and decreased Wnt 
signaling, reduced proliferation potential and increased differentiation phenotype of basal 
mammary stem and/or progenitor cells after pregnancy (see Figure 6.1).  
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Figure 6.1 Schematic illustration of early pregnancy-induced cascade of molecular and 
cellular alterations in mouse mammary epithelial cell subpopulations 
Early pregnancy decreases the proportion of progesterone receptor (PR) positive cells (red 
arrow), which decreases the expression of the Wnt ligand Wnt4 (yellow arrow). This in turn 
reduces Wnt signaling in basal stem and/or progenitor cells (blue arrow), decreasing their 
proliferation potential and inducing a differentiated phenotype. 
 
Although our data suggest a direct causal relation between decreased luminal Wnt4 secretion 
and decreased Wnt signaling and proliferation potential in basal stem and/or progenitor cells, 
the additional involvement of further Wnt ligands cannot be excluded. This relates especially 
to the inhibitor of canonical Wnt signaling Wnt5a. Notably, previous studies in total 
mammary glands have reported an increase in TGFβ signaling after pregnancy which in turn 
stimulates Wnt5a expression (Blakely et al., 2006; Blance et al., 2009; D'Cruz et al., 2002; 
Roarty and Serra, 2007). Wnt5a activates the planar cell polarity and/or the Wnt/calcium 
pathway, which in turn inhibit canonical Wnt signaling (Mikels and Nusse, 2006; Serra et al., 
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2011; Topol et al., 2003; Westfall et al., 2003). Thus, activation of such non-canonical Wnt 
pathways could be involved in addition to reduced mammary Wnt4 expression in the early 
pregnancy-induced decrease of canonical Wnt signaling in basal stem and/or progenitor cells. 
 
Two anti-tumorigenic alterations in mammary glands of parous mice can potentially explain 
the breast cancer protective effect of early pregnancy. First, Wnt inhibition has been shown to 
have potent anti-proliferation and anti-cancer activity (Benad et al., 2011; Ettenberg et al., 
2010; Hallett et al., 2012; King et al., 2012; Prosperi and Goss, 2010). In contrast, increased 
Wnt signaling and elevated proliferation potential in stem and progenitor cells are strongly 
linked to oncogenesis in the mammary gland (Li et al., 2003; Liu et al., 2004; Teuliere et al., 
2005), and over 50% of women with breast cancer have activated canonical Wnt pathway 
promoting tumor progression (Benad et al., 2011; Lindvall et al., 2007). Second, based on the 
hypothesis that estrogen and progesterone receptor (ER/PR) positive breast cancers originate 
from ER/PR positive luminal mammary epithelial cells (Lim et al., 2009), the observed 
parity-induced reduction in the proportion of luminal hormone sensing cells (see Figure 6.1) 
could additionally contribute to decreased risk of breast tumorigenesis following pregnancy. 
Together with a decreased propensity of stem and progenitor cells to proliferate and generate 
new potential cells of tumor origin, the findings in this study are thus consistent with a breast 
cancer protective effect of early pregnancy. This is underscored by the decrease of potentially 
tumorigenic biofunctions as revealed by bioinformatics analyses (see 5.4.3). However, it 
cannot be excluded that besides the decreased functionality of the ER/PR-Wnt4-canonical 
Wnt signaling cascade and its subsequent proliferation defect in basal mammary stem and/or 
progenitor cells other anti-cancer mechanisms might also be involved in the reported breast 
cancer protective effect of an early pregnancy. Thus, the overall significance of Wnt 
inhibition and its molecular and cellular consequences for parity-induced breast cancer 
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protection remain to be demonstrated in long-term studies with synthetic Wnt inhibitors. 
Notably, several Wnt inhibitors are currently in development and at least two have entered 
Phase I trials (Curtin and Lorenzi, 2010). 
 
The life-long nature of parity-induced breast cancer protection indicates the presence of 
possible epigenetic mechanisms downstream of reduced progesterone and/or Wnt signaling in 
specific mammary epithelial cell subtypes. This is especially relevant, because progesterone 
and Wnt signaling have been associated with epigenetic alterations including DNA 
methylation, as well as H3K27 and H3K4 trimethylation (Pal et al., 2013; Wohrle et al., 
2007). Studies on potential parity-induced epigenetic changes in isolated mammary cell 
subpopulations are warranted. 
 
Other open questions remain with respect to the time points of pregnancy and mammary cell 
analyses. In this study, special care was taken to induce pregnancy in mice as early as 
possible (i.e. 42 days). In addition, cell harvest was performed after complete involution had 
occurred (i.e. 40 days after weaning). Hence, the obtained results are related neither to the 
effect of late pregnancy nor to the duration of early parity-induced molecular and cellular 
alterations in mouse mammary epithelial cell subpopulations. Since early but not late 
pregnancy protects against breast cancer and this protective effect is of life-long duration, it 
would be especially interesting to investigate the age-dependent magnitude as well as the 
duration of parity-induced alterations. In this context, eight scenarios are theoretically 
possible. They are illustrated in Figure 6.2. However, not all scenarios are equally relevant, 
since the breast cancer protective effect of parity decreases with increasing age at first full-
term pregnancy (see Figure 3.4.1). Whereas this age-related diminution of the breast cancer 
protective effect could be explained by the greater initial increase in risk immediately 
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following parturition with late first full-term pregnancy (see Figure 3.4.1), age-dependent 
changes in the magnitude and duration of parity-induced cellular and molecular alterations 
can markedly influence the overall breast cancer risk during the entire life span. Hence, in 
order to account for a significant life-long breast cancer protective effect, the early 
pregnancy-induced cellular and molecular alterations in mammary epithelial cell subtypes 
would have to dominate in magnitude and/or duration over late pregnancy-induced changes. 
Consequently, the scenarios 1,2,5,6 and 8 in Figure 6.2 have potentially the greatest 
biological significance. They imply either an equal magnitude but longer duration (scenarios 
1,2), a greater magnitude and longer duration (scenarios 5,6) or a greater magnitude and 
similar duration (scenario 8) of early as compared to late pregnancy-induced cellular and 
molecular alterations in mammary epithelial cell subpopulations. In contrast, the scenarios 
3,4 and 7 have comparatively little biological significance. To differentiate between the 
various possibilities, additional experiments are ongoing examining the magnitude and 
duration of altered expression of estrogen receptor, progesterone receptor, and the classic 
Wnt target versican in mammary glands after late pregnancy (i.e. age of mice at mating: 24 
weeks instead of 6 weeks) and after a considerably longer post-weaning period (i.e. 78 weeks 
instead of 40 days), respectively. Notably, a recent study has already addressed the effect of 
late first full-term pregnancy on mammary gland characteristics in “postmenopausal” mice. 
This study found no changes in estrogen receptor expression and only minor decreases in 
progesterone receptor expression, indicating a reduced influence of late as compared to early 
pregnancy on mammary epithelial cell functionality (Raafat et al., 2012).  
 
  General discussion   
 
 
116 
 
 
 
Figure 6.2 Magnitude and duration of parity-induced cellular and molecular changes in 
mammary epithelial cell subpopulations 
After early and late first full-term pregnancy, eight scenarios are theoretically possible: 1) 
Parity-induced changes are of equal magnitude and of life-long duration after early and late 
pregnancy. 2) Parity-induced changes are of equal magnitude, and life-long after early but 
transient after late pregnancy. 3) Parity-induced changes are of equal magnitude, and 
transient after early but life-long after late pregnancy. 4) Parity-induced changes are of equal 
magnitude but of transient duration after early and late pregnancy. 5) Parity-induced changes 
are of smaller magnitude after late as compared to early pregnancy, but both are of life-long 
duration. 6) Parity-induced changes are of smaller magnitude after late as compared to early 
pregnancy, and life-long after early but transient after late pregnancy. 7) Parity-induced 
changes are of smaller magnitude after late as compared to early pregnancy, and transient 
after early but life-long after late pregnancy. 8) Parity-induced changes are of smaller 
magnitude after late as compared to early pregnancy, but both are of transient duration.  
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In conclusion, this study has identified major early parity-induced cellular and molecular 
alterations in mammary epithelial cell subtypes in mice. Specifically, downregulation of the 
Wnt/Notch signaling ratio and in vitro and in vivo proliferation defects were observed in 
basal mammary stem/progenitor cells. Mechanistically, the observed phenomenon can be 
explained by an early parity-induced reduction in hormone-sensitive and Wnt4-secreting 
luminal cells. Hence, the study provides direct experimental evidence for the hypothesis that 
early pregnancy changes the hormone responsiveness of the mammary gland and alters the 
properties and cell fates of specific mammary epithelial cell subpopulations. Furthermore, it 
opens the door for further studies investigating possibilities to mimic the breast cancer 
protective effect of early pregnancy.  
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List of Abbreviations 
ADAM17/TACE: tumor necrosis factor-α-converting enzyme 
ADH: atypical ductal hyperplasia 
Areg: amphiregulin 
APC: adenomatous polyposis coli 
Axin2: axis inhibition protein 2 
BRCA1: breast cancer 1, early-onset 
BRCA2: breast cancer 2, early-onset 
CD24: cluster of differentiation 24 or heat stable antigen CD24 
CD29: β1-integrin 
CD49f: α6-integrin 
DCIS: ductal carcinoma in situ 
ECM: extracellular matrix 
ER: estrogen receptor 
EGF: epidermal growth factor 
EGFR: epidermal growth factor receptor 
EMT: epithelial-to-mesenchymal transition 
ErbB: erythroblastic leukemia viral oncogene homolog 
FACS: fluorescence-activated cell sorting 
FDR: false discovery rate 
FEA: flat epithelial atypia 
FGF: fibroblast growth factor 
FGFR: fibroblast growth factor receptor 
FWER: family-wise error rate 
Fzd: Frizzled receptor 
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Gata3: GATA binding protein 3 
GH: growth hormone 
GSEA: gene set enrichment analysis 
GSK-3β: glycogen synthase kinase beta 
HER2 (in humans)/Neu (in rodents)/ErbB2: epidermal growth factor receptor 2 
IDC: invasive ductal carcinoma 
IGF: insulin-like growth factor 
IGF-1R: insulin-like growth factor-1 receptor 
Krt14: keratin 14 
Krt18: keratin 18 
LEF/TCF: lymphoid enhancer factor/T-cell-specific transcription factor 
LN: lymph node 
Lrp: LDL-receptor-related protein 
MAML: mastermind-like 
MARA: motif activity response analysis 
MaSCs: mammary stem cells 
MRUs: mammary repopulating units 
NICD: Notch intracellular domain 
N1ICD: intracellular domain of Notch1 
N2ICD: intracellular domain of Notch2 
N3ICD: intracellular domain of Notch3 
N4ICD: intracellular domain of Notch4 
p53: tumor protein 53 
PI-MECs: parity-identified mammary epithelial cells 
PR: progesterone receptor 
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PRL: prolactin 
PrlR: prolactin receptor 
PTEN: phosphatase and tensin homolog 
RANKL: receptor activator for nuclear factor kappaB ligand 
RBCs: red blood cells 
RBP-J: recombination signal binding protein for immunoglobulin kappa J region 
RTK: receptor tyrosine kinase 
qPCR: quantitative PCR 
Sca1: stem cell antigen1 
Sfrp1: secreted frizzled-related protein1 
SMA: smooth muscle actin 
SMAD: mothers against DPP homolog 
TDLU: terminal ductal lobuloalveolar unit 
TEB: terminal end bud 
TGFβ: transforming growth factor beta 
TGFβR: transforming growth factor beta receptor 
TNF: tumor necrosis factor 
WBCs: white blood cells 
Wnt: wingless related protein 
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